Azolidines as β3 adrenergic receptor agonists

ABSTRACT

This invention provides compounds of Formula I having the structure                    
     wherein, A, X, Y, Z, W, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

This application claims the benefit of U.S. Provisional Application No.60/218,706, filed Jul. 17, 2000.

BACKGROUND OF THE INVENTION

This invention relates to azolidine derivatives which are β₃ adrenergicreceptor agonists useful for the treatment of metabolic disordersrelated to insulin resistance or hyperglycemia (typically associatedwith obesity or glucose intolerance), atherosclerosis, gastrointestinaldisorders, neurogenetic inflammation, glaucoma, ocular hypertension, andfrequent urination; and are particularly useful in the treatment of typeII diabetes.

The subdivision of β adrenergic receptors (β-AR) into β₁- and β₂-AR hasled to the development of β₁- and β₂- antagonists and/or agonists whichhave been useful for the treatment of cardiovascular disease and asthma.The recent discovery of “atypical” receptors, later called β₃-AR, hasled to the development of β₃-AR agonists which may be potentially usefulas antiobesity and antidiabetic agents. For recent reviews on β₃-ARagnoists, see: 1. A. D. Strosberg, Annu. Rev. Pharmacol. Toxicol. 1997,37, 421; 2. A. E. Weber, Ann. Rep. Med. Chem. 1998, 33, 193; 3. C. P.Kordik and A. B. Reitz, J. Med. Chem. 1999, 42, 181; 4. C. Weyer, J. F.Gautier and E. Danforth, Diabetes and Metabolism, 1999, 25, 11.

Compounds that are potent and selective β agonists, may be potentiallyuseful antiobesity agents. Low levels or lack of β₁ and β₂-agonisticproperties will minimize or eliminate the adverse side effects that areassociated with β₁ and β₂ agonistic activities, i.e. increased heartrate, and muscle tremor, respectively.

Early developments in the β₃-agonist field are described in Europeanpatent 427480, U.S. Pat. Nos. 4,396,627, 4,478,849, 4,999,377,5,153,210. Although the early developments purport to claim compoundswith greater β₃-AR selectivity over the β₁- and β₂-AR. However, clinicaltrials in humans with those early developed β₃-agonists have, so far,not been successful.

More recently, potent and selective human β₃ agonists have beendescribed in several patents and published applications: WO 98/32753, WO97/46556, WO 97/37646, WO 97/15549, WO 97/25311, WO 96/16938, WO95/29159, European Patents 659737, 801060, 714883, 764640, 827746, andU.S. Pat. Nos. 5,561,142, 5,705,515, 5,436,257, and 5578620. Thesecompounds were evaluated in Chinese hamster ovary (CHO) cells testprocedures, expressing cloned human β3 receptors, which predict theeffects that can be expected in humans (Granneman et al., Mol Pharmacol,1992, 42, 964; Emorine et al., Science, 1989, 245, 1118; Liggett Mol.Pharmacol., 1992, 42, 634).

β₃-Adrenergic agonists also are useful in controlling the frequent urgeof urination. It has been known that relaxation of the bladder detrusoris under beta adrenergic control (Li JH, Yasay GD and Kau STPharmacology 1992; 44:13-18). Beta-adrenoceptor subtypes are in thedetrusor of guinea-pig urinary bladder. Recently, a number oflaboratories have provided experimental evidence of β₃ adrenergicreceptors in a number of animal species including human (Yamazaki Y,Takeda H, Akahane M, Igawa Y, et al. Br. J Pharmacol. 1998; 124:593-599), and that activation of the β₃ receptor subtype bynorepinephrine is responsible for relaxation of the urinary bladder.

Urge urinary incontinence is characterized by abnormal spontaneousbladder contractions that can be unrelated to bladder urine volume. Urgeurinary incontinence is often referred to hyperactive or unstablebladder. Several etiologies exist and fall into two major categories,myogenic and neurogenic. The myogenic bladder is usually associated withdetrusor hypertrophy secondary to bladder outlet obstruction, or withchronic urinary tract infection. Neurogenic bladders are associated withan uninhibited micturition reflex. An upper motor neuron disease isusually the underlying cause. In either case, the disease ischaracterized my abnormal spontaneous contractions that result in anabnormal sense of urinary urgency and involuntary urine loss. Atpresent, the most common therapy for hyperactive bladder includes theuse of antimuscarinic agents to block the action of the excitatoryneurotransmitter acetylcholine. While effective in neurogenic bladders,their utility in myogenic bladders is questionable. In addition, due tosevere dry mouth side-effects associated with antimuscarinic therapy,the patient compliance with these agents is only approximately 30%.

In the bladder, β₃ adrenergic receptor agonists activate adenylylcyclase and generate cAMP through the G-protein coupled β₃ receptor. Theresulting phosphorylation of phospholamban/calcium ATPase enhancesuptake of calcium into the sarcoplasmic reticulum. The decrease inintracellular calcium inhibits bladder smooth muscle contractility.

It is suggested therefore, that activation of the β₃ adrenergic receptorin the urinary bladder will inhibit abnormal spontaneous bladdercontractions and be useful for the treatment of bladder hyperactivity.Note, that unlike the antimuscarinics, β₃ adrenergic receptor agonistswould be expected to be active against both neurogenic and myogenicetiologies.

Despite all these recent developments there is still no single therapyavailable for the treatment of type II diabetes (NIDDM), obesity,atherosclerosis, gastrointestinal disorders, neurogenetic inflammation,frequent urination and related diseases. A potent and selective β₃adrenergic receptor agonist is therefore highly desirable for thepotential treatment of such disease states.

DESCRIPTION OF THE INVENTION

This invention provides compounds of Formula I having the structure

wherein,

R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6 carbon atoms,aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbon atoms, halogen,trifluoromethyl of 1-6 carbon atoms, arylalkoxy of 7-14 carbon atoms,arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy,nitro, amino, aminocarbonyl, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, formamido, ureido, acyl of2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S;

R₄ is hydrogen or alkyl of 1-6 carbon atoms;

R₅ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms,arylalkyl of 7-14 carbon atoms, halogen substituted arylalkyl of 7-14carbon atoms, arylalkene of 8-16 carbon atoms, arylalkyne of 8-16 carbonatoms, alkoxycarbonyl of 2-7 carbon atoms, aryloxycarbonyl of 7-11carbon atoms, alkylsulfonyl of 1-6 carbon atoms, or arylsulfonyl of 1-6carbon atoms;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, aryl or arylalkyl of 7-14carbon atoms;

A is phenyl, naphthyl, benzofuryl, or benzothienyl;

X is bond, —OCH₂—, or —SCH₂—;

Y is alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;

Z is carbon, sulfur, oxygen, or nitrogen;

W is carbon or nitrogen;

or a pharmaceutically acceptable salt thereof, which are selectiveagonists at human β₃ adrenergic receptors and are useful in treating orinhibiting metabolic disorders related to insulin resistance orhyperglycemia (typically associated with obesity or glucoseintolerance), atherosclerosis, gastrointestinal disorders, neurogeneticinflammation, glaucoma, ocular hypertension, and frequent urination; andare particularly useful in the treatment or inhibition of type IIdiabetes.

Pharmaceutically acceptable salts can be formed from organic andinorganic acids, for example, acetic, propionic, lactic, citric,tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic,hydrochloric, hydrobromic, phosphoric, nitric, sulfuric,methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic,camphorsulfonic, and similarly known acceptable aids when a compound ofthis invention contains a basic moiety. Salts may also be formed fromorganic and inorganic bases, such as alkali metal salts (for example,sodium, lithium, or potassium) alkaline earth metal salts, ammoniumsalts, alkylammonium salts containing 1-6 carbon atoms ordialkylammonium salts containing 1-6 carbon atoms in each alkyl group,and trialkylammonium salts containing 1-6 carbon atoms in each alkylgroup, when a compound of this invention contains an acidic moiety.

Alkyl includes both straight chain as well as branched moieties. Alkenyland alkynyl include both straight chain as well as branched moities,which contain at least one alkene or alkyne group. By definition alkylalso includes alkyl moieties which are optionally mono- or polysubstituted with groups such as halogen, hydroxy, cyano, alkoxy,aryloxy, arylalkyl, alkylthio, arylthio, amino, alkylamino, anddialkylamino. Halogen means bromine, chlorine, fluorine, and iodine.Preferred aryl moieties are phenyl and naphthyl.

As used herein, a heterocyclic ring is a ring contining 1-3 heteroatomsselected from N, O, and S, which may be saturated, unstaurated, orpartially unsaturated. It is understood that the heterocyclic ring doesnot contain heteroatoms in arrangements which would make them inherentlyunstable. For example, the term heterocyclic ring does not include ringsystems containing O-O bonds in the ring backbone. When any two of R₁,R₂, or R₃ are taken together to form a heterocyclic ring, the resultingheterocycle will be fused to a phenyl ring. Either ring of the phenylfused heterocycle may contain the R₁, R₂, or R₃ substitutent which isnot part of the ring backbone. Similarly when any two R₁, R₂, or R₃ aretaken together to form a phenyl ring, the resulting moiety will be anaphthyl ring. Either ring of the naphthyl moiety may contain the R₁,R₂, or R₃ substitutent which is not part of the ring backbone. When twoof R₁, R₂, or R₃ are taken together to form a heterocyclic ring,preferred phenyl fused heterocyclic rings include benzimidazolone andcarbazole.

The compounds of the present invention contain at least one asymmetriccenter. Additional asymmetric centers may exist on the moleculedepending upon the structure of the substituents on the molecule. Thecompounds may be prepared as a racemic mixture and can be used as such,or may be resolved into the . In addition to covering the racemiccompounds, this invention also covers all individual isomers,enantiomers, diasteromers or mixtures thereof, regardless of whether thestructural representations of the compounds indicate suchstereochemistry.

Preferred compounds of Formula I are those in which

R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6 carbon atoms,aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbon atoms, halogen,arylalkoxy of 7-14 carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxyof 1-6 carbon atoms, hydroxy, or alkylsulfonylamino of 1-6 carbon atoms;or two of R₁, R₂, and R₃ are taken together to form a heterocyclic ringwhich is fused to the ring which contains the R₁, R₂, or R₃substituents, wherein the heterocyclic ring contains 1-3 heteroatomsselected from N, O, or S;

R₄ is hydrogen or alkyl of 1-6 carbon atoms;

R₅ is hydrogen, alkyl of 1-6 carbon atoms, halogen substituted arylalkylof 7-14 carbon atoms, or arylalkyne of 8-16 carbon atoms;

R₆ is hydrogen, or alkyl of 1-6 carbon atoms;

A is phenyl, or benzofuryl;

X is bond, or —OCH₂—;

Y is alkyl of 1-6 carbon atoms;

Z is sulfur;

W is carbon or nitrogen;

or a pharmaceutically acceptable salt thereof.

Specifically preferred compounds of this invention are:

a) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-phenoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

b) 5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-3-methyl-1,3-thiazolidine-2,4-dione;

c) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)anilino]-3-methyl-1,3-thiazolidine-2,4-dione;

d) 5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione;

e) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

f) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxy-ethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

g) 5-[4-(2-{[(2R)-2-Hydroxy-2-phenylethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

h) 5-[4-(2-{[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropy]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

i) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

j) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-methoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

k) 5-{4-[2-({(2S)-3-[3-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione;

l) 5-[4-(2-{[(2S)-2-Hydroxy-3-(3-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

m) 5-[4-(2-{[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

n) N-{5-[( 1S)-2-({4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

o) 5-[4-(2-{[(2S)-3-(1-Benzofuran-5-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

p) 5-[4-(2-{[(2S)-3-(4-Butoxyphenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione;

q) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)(methyl)anilino]-1,3-thiazolidine-2,4-dione;

r) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}propyl)anilino]-1,3-thiazolidine-2,4-dione;

s) 5-{4-[2-({(2 R)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione;

t) 5-{[2-({[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}methyl)-1-benzofuran-5-yl]amino}-1,3-thiazolidine-2,4-dione;

u) 5-(4-{2-[(2S)-2-Hydroxy-3-(naphthalen-2-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione;

v) 5-(4-{2-[(2 S)-3-(Biphenyl-4-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione;

w)5-(4-{2-[2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione;

x) 5-(4-{2-[(2S)-3-(Benzo[1,3]dioxol-5-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione;

y) 5-(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione;

z) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-(4-bromo-benzyl)-amino]-thiazolidine-2,4-dione;

aa) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-methyl-amino]-thiazolidine-2,4-dione;

bb) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-[3-{4-fluoro-phenyl)-prop-2-ynyl]-amino}-thiazolidine-2,4-dione;

cc) 5-[(4-Bromo-benzyl)-(4-{2-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-phenyl)-amino]-thiazolidine-2,4-dione;

dd) 5-[(4-Bromo-benzyl)-{4-[2-((2 S)-2-hydroxy-3-phenoxy-propylamino)-ethyl]-phenyl}-amino)-thiazolidine-2,4-dione;

ee) 5-{4-[2-((2S)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylamino}-thiazolidine-2,4-dione;and

ff) 5-{4-[2-((2R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylamino}-thiazolidine-2,4-dione

or a pharmaceutically acceptable salt thereof.

The compounds of this invention were be prepared according to thefollowing schemes from commercially available starting materials orstarting materials which can be prepared using literature procedures.These schemes show the preparation of representative compounds of thisinvention.

In Scheme I, hydroxyl compounds of structure 1 which are eithercommercially available or can be prepared by known methods (ref. EP0764640), can be alkylated with glycidyl benzenesulfonates 2 in thepresence of a base, i.e. sodium hydride to produce epoxides 3. Styreneoxides that were used in this invention were commercially available.Refluxing either epoxides 3 or styrene oxides with aniline 4 producedcompounds 5. The amino group can be protected selectively usingdi-tert-butyl dicarbonate at low temperatures (0° C.) to produce 10carbamates 6. Treatment of the carbamates 6 withbromo-thiazolidinediones 7 in the presence of a base, i.e.triethylamine, in polar solvents, i.e. N,N-dimethylformamide, followedby acidic hydrolysis with either organic or inorganic acids, i.e.trifluoroacetic acid, produced thiazolidinediones 8. The requiredbromo-thiazolidinediones 7 were prepared according to known methods(ref. J. Med. Chem., 1990, 33 1418-1423). Alkylation of 6 with various15 alkylating agents 9 in the presence of a base, i.e. potassiumcarbonate, produced anilines 10.

Substituted anilines 10 react with the bromo-thiazolidinediones 7,similarly to anilines 6, to produce alkylated analogues 8.

In Scheme II, nitrobenzene 11 was treated with acetoxime in the presenceof a base, i.e. sodium hydride, followed by treatment with an ethanolicsolution of hydrochloric acid to produce benzofuran 13. Bromination of13 with 1,3-dibromo-5,5-dimethylhydantoin under UV light gave bromide15. Conversion of 13 to amine 16 was accomplished in two steps, firstalkylation with potassium phthalimide in acetonitrile in the presencecrown ether (18-C-6), followed by hydrolysis with hydrazine/ethanol.Amine 16 was converted to the thiazolidinedione 17, in substantially thesame manner as in Scheme I.

The compounds of this invention are useful in treating metabolicdisorders related to insulin resistance or hyperglycemia, typicallyassociated with obesity or glucose intolerance. The compounds of thisinvention are therefore, particularly useful in the treatment orinhibition of type II diabetes. The compounds of this invention are alsouseful in modulating glucose levels in disorders such as type Idiabetes.

The ability of compounds of this invention to treat or inhibit disordersrelated to insulin resistance or hyperglycemia was established withrepresentative compounds of this invention in the following standardpharmacological test procedures, which measured the binding selectivityto the β₁, β₂, and β₃ adrenergic receptors. Binding to the receptors wasmeasured in Chinese Hamster ovary (CHO) cells that were transfected withadrenergic receptors. The following briefly summarizes the proceduresused and results obtained.

Transfection of CHO cells with β₁ and β₂ adrenergic receptors: CHO cellswere transfected with human β₁- or β₂-adrenergic receptors as describedin Tate, K. M., Eur. J. Biochem., 196:357-361 (1991).

Cloning of Human β₃-AR Genomic DNA: cDNA was constructed by ligatingfour polymerase chain reaction (PCR) products using the followingprimers: an ATG-Narl fragment, sense primer5′-CTTCCCTACCGCCCCACGCGCGATC3′ and anti-sense primer5′CTGGCGCCCAACGGCCAGTGGCCAGTC3′; a Narl-Accl fragment,5′TTGGCGCTGATGGCCACTGGCCGTTTG3′ as sense and5′GCGCGTAGACGAAGAGCATCACGAG3′ as anti-sense primer; an Accli-Stylfragment, sense primer 5′CTCGTGATGCTCTTCGTCTCACGCGC3′ and anti-senseprimer 5′GTGMGGTGCCCATGATGAGACCCAAGG3′ and a Styl-TAG fragment, withsense primer 5′CCCTGTGCACCTTGGGTCTCATCATGG3′ and anti-sense primer5′CCTCTGCCCCGGTTACCTACCC3′. The corresponding primer sequences aredescribed in Mantzoros, C. S., etal, Diabetes 45: 909-914 (1996). Thefour fragments are ligated into a pUC 18 plasmid (Gibco-BRL) andsequenced. Full length β₃ AR clones (402 amino acids) containing thelast 6 amino acids of hβ₃ . . . AR are prepared with the β₃-βARpcDNA3from ATTC.

Binding Procedure: Clones expressing receptor levels of 70 to 110fmoles/mg protein were used in the test procedures. CHO cells were grownin 24-well tissue culture plates in Dulbecco's Modified Eagle Media with10% fetal bovine serum, MEM non-essential amino acids,Penicillin-Streptompycin and Geneticin. On the day of test procedure,growth medium was replaced with preincubation media (Dulbecco's ModifiedEagle Media and incubated for 30 minutes at 37° C. Preincubation mediumwas replaced with 0.2 ml treatment medium containing DMEM mediacontaining 250 μM IBMX (isobutyl-1-methylxantine) plus 1 mM ascorbicacid with test compound dissolved in DMSO. Test compounds were testedover a concentration range of 10⁻⁹ M to 10⁻⁵ M for β₃ cells and 10^(″8)to 10^(″4) M for β₁ and β₂ transfected cells. Isoproterenol (10⁻⁵ M) wasused as an internal standard for comparison of activity. Cells wereincubated at 37° C. on a rocker for 30 min with the β₃ cells and 15 minfor β₁ and β₂ cells. Incubation was stopped with the addition of 0.2 NHCI and neutralized with 2.5 N NaOH. The plates, containing the cellsand neutralized media, were stored at −20 degrees celsius until ready totest for cAMP using the SPA test kit (Amersham).

Data Analysis and Results: Data collected from the SPA test procedurewere analyzed as percent of the maximal isoproterenol response at 10⁻⁵M. Activity curves were plotted using the SAS statistical and graphicssoftware. EC₅₀ values were generated for each compound and the maximalresponse (IA) developed for each compound is compared to the maximalresponse of isoproternol at 10⁻⁵ M from the following formula:${IA} = \frac{\% \quad {activity}\quad {compound}}{\% \quad {activity}\quad {isoproterenol}}$

Table I shows the β₃-adronergic receptor EC₅₀ and IA values for therepresentative compounds of this invention that were evaluated in thisstandard pharmacological test procedure. These results show thatcompounds of the present invention have activity at the β₃-adrenergicreceptor. The compounds of this inventon had weaker or no activity at β₁and/or β₂-adrenergic receptor.

TABLE I Compound No. EC₅₀(β3, nM) IA(β3) Example 4 1 85 Example 5 20 99Example 6 7 83 Example 7 83 94 Example 8 14 66 Example 9 0.9 98 Example12 3 117 Example 13 12 104 Example 14 9 111 Example 17 17 68 Example 189 89 Example 19 20 71 Example 29 3 109 Example 31 96 88

Based on the results obtained in these standard pharmacological testprocedures, representative compounds of this invention have been shownto be selective β₃ adrenergic receptor agonists and are therefore usefulin treating metabolic disorders related to insulin resistance orhyperglycemia (typically associated with obesity or glucoseintolerance), atherosclerosis, gastrointestinal disorders, neurogeneticinflammation, glaucoma, ocular hypertension, and frequent urination; andare particularly useful in the treatment or inhibition of type IIdiabetes, and in modulating glucose levels in disorders such as type Idiabetes. As used herein, the term modulating means maintaining glucoselevels within clinically normal ranges.

As used in accordance with this invention, the term providing aneffective amount means either directly administering such a compound ofthis invention, or administering a prodrug, derivative, or analog whichwill form an effective amount of the compound of this invention withinthe body.

It is understood that the effective dosage of the active compounds ofthis invention may vary depending upon the particular compound utilized,the mode of administration, the condition, and severity thereof, of thecondition being treated, as well as the various physical factors relatedto the individual being treated. As used in accordance with invention,satisfactory results may be obtained when the compounds of thisinvention are administered to the individual in need at a daily dosageof from about 0.1 mg to about 1 mg per kilogram of body weight,preferably administered in divided doses two to six times per day, or ina sustained release form. For most large mammals, the total daily dosageis from about 3.5 mg to about 140 mg. It is preferred that theadministration of one or more of the compounds herein begin at a lowdose and be increased until the desired effects are achieved.

Such doses may be administered in any manner useful in directing theactive compounds herein to the recipient's bloodstream, includingorally, via implants, parenterally (including intravenous,intraperitoneal and subcutaneous injections), rectally, intranasally,vaginally, and transdermally. For the purposes of this disclosure,transdermal administrations are understood to include alladministrations across the surface of the body and the inner linings ofbodily passages including epithelial and mucosal tissues. Suchadministrations may be carried out using the present compounds, orpharmaceutically acceptable salts thereof, in lotions, creams, foams,patches, suspensions, solutions, and suppositories (rectal and vaginal).

Oral formulations containing the active compounds of this invention maycomprise any conventionally used oral forms, including tablets,capsules, buccal forms, troches, lozenges and oral liquids, suspensionsor solutions. Capsules may contain mixtures of the active compound(s)with inert fillers and/or diluents such as the pharmaceuticallyacceptable starches (e.g. corn, potato or tapioca starch), sugars,artificial sweetening agents, powdered celluloses, such as crystallineand microcrystalline celluloses, flours, gelatins, gums, etc. Usefultablet formulations may be made by conventional compression, wetgranulation or dry granulation methods and utilize pharmaceuticallyacceptable diluents, binding agents, lubricants, disintegrants,suspending or stabilizing agents, including, but not limited to,magnesium stearate, stearic acid, talc, sodium lauryl sulfate,microcrystalline cellulose, carboxymethylcellulose calcium,polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum,sodium citrate, complex silicates, calcium carbonate, glycine, dextrin,sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose,kaolin, mannitol, sodium chloride, talc, dry starches and powderedsugar. Oral formulations herein may utilize standard delay or timerelease formulations to alter the absorption of the active compound(s).

In some cases it may be desirable to administer the compounds directlyto the airways in the form of an aerosol.

The compounds of this invention may also be administered parenterally orintraperitoneally. Solutions or suspensions of these active compounds asa free base or pharmacologically acceptable salt can be prepared inwater suitably mixed with a surfactant such as hydroxy-propylcellulose.Dispersions can also be prepared in glycerol, liquid polyethyleneglycols and mixtures thereof in oils. Under ordinary conditions ofstorage and use, these preparation contain a preservative to prevent thegrowth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterileaqueous solutions or dispersions and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersions. In all cases, the form must be sterile and must be fluid tothe extent that easy syringability exists. It must be stable under theconditions of manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (e.g., glycerol, propylene glycol and liquidpolyethylene glycol), suitable mixtures thereof, and vegetable oils.

Suppository formulations may be made from traditional materials,including cocoa butter, with or without the addition of waxes to alterthe suppository's melting point, and glycerin. Water soluble suppositorybases, such as polyethylene glycols of various molecular weights, mayalso be used.

The compounds of the present invention also possess utility forincreasing lean meat deposition and/or improving lean meat to fat ratioin edible animals, i.e. ungulate animals and poultry.

Animal feed compositions effective for increasing lean meat depositionand for improving lean meat to fat ratio in poultry, swine, sheep,goats, and cattle are generally prepared by mixing the compounds of thepresent invention with a sufficient amount of animal feed to providefrom about 1 to 1000 ppm of the compound in the feed. Animal feedsupplements can be prepared by admixing about 75% to 95% by weight of acompound of the present invention with about 5% to about 25% by weightof a suitable carrier or diluent. Carriers suitable for use to make upthe feed supplement compositions include the following: alfalfa meal,soybean meal, cottonseed oil meal, linseed oil meal, sodium chloride,cornmeal, cane molasses, urea, bone meal, corncob meal and the like. Thecarrier promotes a uniform distribution of the active ingredients in thefinished feed into which the supplement is blended. It thus performs animportant function by ensuring proper distribution of the activeingredient throughout the feed. The supplement is used as a top dressingfor the feed, it likewise helps to ensure uniformity of distribution ofthe active material across the top of the dressed feed.

The preferred medicated swine, cattle, sheep and goat feed generallycontain from 0.01 to 400 grams of active ingredient per ton of feed, theoptimum amount for these animals usually being about 50 to 300 grams perton of feed. The preferred poultry and domestic pet feed usually containabout 0.01 to 400 grams and preferably 10 to 400 grams of activeingredient per ton of feed.

For parenteral administration the compounds of the present invention maybe prepared in the form of a paste or a pellet and administered as animplant, usually under the skin of the head or ear of the animal inwhich increase in lean meat deposition and improvement in lean mean tofat ratio is sought. In general, parenteral administration involvesinjection of a sufficient amount of the compounds of the presentinvention to provide the animal with 0.001 to 100 mg/kg/day of bodyweight of the active ingredient. The preferred dosage for swine, cattle,sheep and goats is in the range of from 0.001 to 50 mg/kg/day of bodyweight of active ingredient; whereas, the preferred dose level forpoultry and domestic pets is usually in the range of from 0.001 to 35mg/kg/day of body weight.

Paste formulations can be prepared by dispersing the active compounds ina pharmaceutically acceptable oil such as peanut oil, sesame oil, cornoil or the like. Pellets containing an effective amount of the compoundsof the present invention can be prepared by admixing the compounds ofthe present invention with a diluent such as carbowax, carnuba wax, andthe like, and a lubricant, such as magnesium or calcium stearate, can beadded to improve the pelleting process. It is, of course, recognizedthat more than one pellet may be administered to an animal to achievethe desired dose level which will provide the increase in lean meatdeposition and improvement in lean meat to fat ratio desired. Moreover,it has been found that implants may also be made periodically during theanimal treatment period in order to maintain the proper drug level inthe animal's body. For the poultry and swine raisers, using the methodof the present invention yields leaner animals.

Additionally, the compounds of this invention are useful in increasingthe lean mass to fat ratio in domestic pets, for the pet owner orveterinarian who wishes to increase leanness and trim unwanted fat frompet animals, the present invention provides the means by which this canbe accomplished.

The following procedures describe the preparation of representativeexamples of this invention.

EXAMPLE 1

5-[4-(2-{[(2S)-2-Hydroxy-3-(4-phenoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-[(4-Phenoxyphenoxy)methyl]oxirane

Sodium hydride (60% in mineral oil, 1.08 g, 26.9 mmol) was addedportionwise into a cold (0° C.) mixture of 4-phenoxyphenol (5.0 g, 26.9mmol) and N,N-dimethylformamide (50 mL). The mixture was stirred for 1hour and then (2 S)-oxiranylmethyl 3-nitrobenzenesulfonate (7.67 g, 29.6mmol) in N,N-dimethylformamide (10 mL) was added dropwise. The newmixture was stirred at room temperature for 18 hours, poured into waterand extracted with ethyl acetate. The organic extracts were dried overMgSO₄. Evaporation and purification by flash chromatography(hexanes/ethyl acetate 5/1) gave a clear oil (6.2 g, 95% yield): MS mle242 M⁺.

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-(4-phenoxyphenoxy)-2-propanol

A mixture of (2 S)-2-[(4-phenoxyphenoxy)methyl]oxirane (6.0 g, 24.8mmol), 4-(2-aminoethyl)aniline (10.1 g, 74.4 mmol), and methyl alcohol(100 mL) was refluxed for 5 hours. The volatiles were removed in vacuoand the residue was purified by flash chromatography (hexanes/ethylacetate/methyl alcohol 1/1/1) to give a white solid (6.6 g, 70% yield):MS mle 379 (M+H)⁺;

Analysis for: C₂₃H₂₆N₂O₃ Calc'd: C, 72.99; H, 6.93; N, 7.40 Found: C,72.41; H, 6.93; N, 7.33

Step c) tert-Butyl 4-aminophenethyl[(2 S)-2-hydroxy-3-(4-phenoxyphenoxy)propyl]carbamate

Di-tert-butyl dicarbonate (2.88 g, 13.2 mmol) was added into a cold (0°C.) mixture of (2S)-1-[(4-aminophenethyl)amino]-3-(4-phenoxyphenoxy)-2-propanol (5.0 g,13.2 mmol), and tetrahydrofuran (20 mL). The mixture was stirred at 0°C. for 2 hours , poured into water, and extracted with ethyl acetate.The organic extracts were dried over MgSO₄. Evaporation and purificationby flash chromatography (hexaneslethyl acetate 1/1) gave a yellow oil(5.96 g, 95% yield): MS mle 479 (M+H)⁺;

Analysis for: C₂₈H₂₄N₂O₅ Calc'd: C, 70.27; H, 7.16; N, 5.85 Found: C,70.14; H, 6.88; N, 5.73

Step d) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-phenoxyphenoxy)propyl]carbamate

Triethylamine (1.53, 10.97 mmol) was added into a mixture of tert-butyl4-aminophenethyl[(2 S)-2-hydroxy-3-(4-phenoxyphenoxy)propyl]carbamate(5.2 g, 10.97 mmol), 5-bromo-1,3-thiazolidine-2,4-dione (2.15 g, 10.97mmol), and N,N-dimethylformamide (50 mL). The mixture was stirred atroom temperature for 2 hours, poured into aqueous ammonium chloride andextracted with ethyl acetate. The organic extracts were dried overMgSO₄. Evaporation and purification by flash chromatography(hexanes/ethyl acetate 1/1) gave an off-white solid (5.1 g, 78% yield):MS m/e 594 (M+H)⁺;

Analysis for: C₃₁H₃₅N₃O₅S Calc'd: C, 62.72; H, 5.94; N, 7.08 Found: C,62.07; H, 5.93; N, 7.02

Step e) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-phenoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

A mixture of tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-phenoxyphenoxy)propyl]carbamate (1.5 g, 2.53 mmol),trifluoroacetic acid (5 mL) and dichloromethane (50 mL) was stirred atroom temperature for 24 hours. The volatiles were removed in vacuo andthe residue was triturated with ethyl ether to produce a yellow solid(1.32 g, 72% yield): mp 72-74° C.; MS mle 494 (M+H)⁺;

Analysis for: C₂₆H₂₇N₃O₅S×1.6 CF₃CO₂H Calc'd: C, 51.88; H, 4.23; N, 6.21Found: C, 51.73; H, 4.39; N, 6.13

EXAMPLE 2

5-{4-[2-({(2S)-3-[4-(Benzyloxy}phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-3-methyl-1,3-thiazolidine-2,4-dione

Step a) tert-Butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate Di-tert-butyldicarbonate (1.2 g, 5.53 mmol) was added into a cold (0° C.) mixture of(2 S)-1-[(4-aminophenethyl)amino]-3-[4-(benzyloxy)phenoxy]-2-propanol(2.17 g, 5.53 mmol), and tetrahydrofuran (20 mL). The mixture wasstirred at 0° C. for 2 hours, poured into water, and extracted withethyl acetate. The organic extracts were dried over MgSO₄. Evaporationand purification by flash chromatography (hexanes/ethyl acetate 1/1)gave a yellow oil (2.4 g, 88% yield): MS m/e 493 (M+H)⁺;

Step b) 3-Methyl-1,3-thiazolidine-2,4-dione

A mixture of N-methylthiourea (45 g, 0.5 mol), chloroacetic acid (47 g,0.5 mol) and water (250 mL) was refluxed for 48 hours. The mixture wascooled to room temperature and extracted with chloroform. The organicextracts were dried over MgSO₄. Evaporation and purification by flashchromatography (hexanes/ethyl acetate 1/2) gave an off-white solid (51.6g, 79% yield): mp 39-41° C.; MS mle 131 M⁺;

Analysis for: C₄H₅NO₂S Calc'd: C, 36.63; H, 3.84; N, 10.68 Found: C,36.68; H, 3.46; N, 10.44

Step c) 5-Bromo-3-methyl-1,3-thiazolidine-2,4-dione

Bromine (2.16 mL, 42 mmol) was added dropwise into a cold (0° C.)solution of 3-methyl-1,3-thiazolidine-2,4-dione (5.5 g, 42 mmol), andacetic acid (100 mL). The mixture was allowed to come to roomtemperature, and then warmed to 60° C. and stirred for 18 hours. Themixture was then poured into water and extracted with ethyl acetate. Theorganic layer was washed with sodium bisulfite and brine. The organicextracts were dried over MgSO₄. Evaporation and purification by flashchromatography (hexanes/ethyl acetate 1/3) gave a clear oil (7.2 g, 82%yield): MS m/e 209 M⁺;

Analysis for: C₄H₄BrNO₂S Calc'd: C, 22.87; H, 1.92; N, 6.67 Found: C,22.49; H, 1.69; N, 6.52

Step d) 5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-3-methyl-1,3-thiazolidine-2,4-dione

A mixture of tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate (1.2 g, 2.44mmol), 5-bromo-3-methyl-1,3-thiazolidine-2,4-dione (0.51 g, 2.44 mmol),and N,N-dimethylformamide (15 mL) was stirred at room temperature for 48hours. The mixture was then poured into aqueous ammonium chloride andextracted with ethyl acetate. The organic extracts were dried overMgSO₄. Evaporation and purification by flash chromatography(hexanes/ethyl acetate 1/1) gave a light yellow solid (0.72 g, 57%yield): mp 165-167; MS m/e 520 (M−H)⁺;

Analysis for: C₂₈H₃₁N₃O₅S×1 HBr Calc'd: C, 55.91; H, 5.32; N, 6.98Found: C, 56.86; H, 5.28; N, 7.30

EXAMPLE 3

5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)anilino]-3-methyl-1,3-thiazolidine-2,4-dione

Step a) tert-Butyl 4-aminophenethyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate

Di-tert-butyl dicarbonate (4.95 g, 22.72 mmol) was added into a cold (0°C.) mixture of (1R)-2-[(4-aminophenethyl)amino]-1-(3-chlorophenyl)-1-ethanol (6.6 g,22.72 mmol), and tetrahydrofuran (30 mL). The mixture was stirred at 0°C. for 2 hours, poured into water, and extracted with ethyl acetate. Theorganic extracts were dried over MgSO₄. Evaporation and purification byflash chromatography (ethyl acetate/methyl alcohol 5/1) gave a yellowoil (7.4 g, 83% yield): MS m/e 390 M⁺;

Analysis for: C₂₁H₂₇CIN₂O₃ Calc'd: C, 64.52; H, 6.96; N, 7.17 Found: C,63.49; H, 6.49; N, 6.71

Step b) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)anilino]-3-methyl-1,3-thiazolidine-2,4-dione

A mixture of tert-butyl 4-aminophenethylf(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (1.9 g, 4.85 mmol),5-bromo-3-methyl-1,3-thiazolidine-2,4-dione (1.02 g, 4.85 mmol), andN,N-dimethylformamide (15 mL) was stirred at 60° C. for 24 hours. Themixture was then poured into aqueous ammonium chloride and extractedwith ethyl acetate. The organic extracts were dried over MgSO₄.Evaporation and purification by flash chromatography (ethylacetate/methyl alcohol 20/1) gave an oil (1.82 g) which was taken indichloromethane (50 mL) and treated with trifluoroacetic acid (5 mL) for36 hours. The volatiles were then removed in vacuo and the residue waspurified by flash chromatography (ethyl acetate/methyl alcohol 10/1) togive a light yellow solid (1.2 g, 60% yield): mp 129-131; MS m/e 420(M+H)⁺;

Analysis for: C₂₀H₂₂CIN₃O₃S Calc'd: C, 57.20; H, 5.28; N, 10.01 Found:C, 56.99; H, 5.30; N, 9.58

EXAMPLE 4

5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-{[4-(Benzyloxy)phenoxy]methyl}oxirane

Sodium hydride (60% in mineral oil, 2.2 g, 54.0 mmol) was addedportionwise into a cold (0° C.) mixture of 4-(benzyloxyphenol 9.26 g,46.29 mmol) and N, N-dimethylformamide (25 mL). The mixture was stirredfor 1 hour and then (2 S)-(+)-oxiranylmethyl 3-nitrobenzenesulfonate (10g, 38.5 mmol) in N, N-dimethylformamide (25 mL) was added dropwise. Thenew mixture was warmed up to room temperature, stirred for 18 hours,poured into water, and extracted with ethyl acetate. The organicextracts were washed with brine, and dried over MgSO₄. Evaporation andpurification by flash chromatography (hexanes/ethyl acetate 9/1) gave awhite solid (6.2 g, 62% yield), MS m/e 256 (M)⁺; ¹H NMR (DMSO-d₆ 300MHz) δ2.68 (m, 1 H), 3.28 (m, 1 H), 3.74 (m,1 H), 4.21 (m,1 H), 5.02 (s,2 H), 6.91 (m, 4 H), 7.40 (m, 5 H); Analysis for C₁₆H₁₆N₄O₃ Calc'd: C,74.98; H, 6.29 Found: C, 74.46, H, 6.32.

Step b) (2S)-1-[(4-Aminophenethyl)amino]-3-[4-(benzyloxy)phenoxy]-2-propanol

This compound was prepared from (2S)-2-{[4-(benzyloxy)phenoxy]methyl}oxirane and 4-(2-aminoethyl)anilineas described in example 1, step b, with one modification, the mixturewas stirred in tetrahydrofuran and the product was triturated with ethylether to give a white solid (47% yield): MS m/e 393 (M+H )⁺; ¹H NMR(DMSO-d₆ 300 MHz) δ1.61 (br 2 H), 2.75 (m, 3 H), 2.85 (m, 3 H), 3.56 (s,2 H), 3.97 (m, 2 H), 3.99 (m, 1 H), 5.01 (s, 2 H), 6.63 (m, 2 H), 6.81(m, 2 H), 6.82 (m, 2 H), 6.83 (m, 2 H), 7.37 (m, 5 H);

Analysis for C₂₄H₂₈N₂O₃ Calc'd: C, 73.44; H, 7.19; N, 7.14 Found: C,73.02; H, 7.15; N, 6.86.

Step c) tert-Butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-[4-(benzyloxy)phenoxy]-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as colorless oil (85% yield), MSm/e 492 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.45 (s, 9 H), 2.71 (m, 2 H),3.41 (m, 4 H), 3.44 (m, 2 H), 3.86 (m, 2 H), 4.11 (m, 2 H), 5.01 (s, 2H), 6.62 (d, 2 H), 6.83 (d, 2 H), 6.91 (m, 4 H), 7.37 (m, 5 H).

Step d ) tert-Butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as yellow foam solid(66% yield): MS mle 607 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.44 (s, 9 H),1.70 (br, 1 H), 2.79 (m, 2 H), 3.44 (m, 4 H), 3.82 (m, 2 H), 4.08 (m, 1H), 4.58 (d, 1 H), 5.01 (s, 2 H), 6.07 (d, 1 H), 6.61 (d, 2 H), 6.81 (d,2 H), 6.91 (m, 2 H), 7.08 (m, 2 H), 7.41 (m, 5 H), 8.8 (br,1 H).

Step e) 5-{4-[2-({(2 S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, with one modification, the product was isolated asthe free base and recrystallized from methanol, tetrahydrofuran, hexanesto give a yellow foam solid (58% yield): mp 152° C.; MS m/e 508 (M+H)⁺;¹H NMR (DMSO-d₆ 300 MHz) δ2.68 (m, 2 H), 2.81 (m, 1 H), 2.88 (m, 4 H),3.85 (m, 2 H), 4.00 (m, 1 H), 5.02 (s, 2 H), 5.45 (br, 1 H), 5.99 (d, 1H), 6.59 (d, 2 H), 6.66 (d, 1 H), 6.84 (d, 2 H), 6.86 ( m, 2 H) 6.92 (m,2 H), 7.28 (m, 5 H), 8.80 (br, 1 H);

Analysis for C₂₇H₂₉N₃O₅ Calc'd: C, 63.89; H, 5.76; N, 8.28 Found: C,63.91; H, 5.90; N, 7.93.

EXAMPLE 5

5-[4-(2-{[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) tert-Butyl 4-aminophenethyl[(2 S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate

A mixture of tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate (1.2 g, 2.53mmol), 10% Pd/C (0.1 g), and ethanol (30 mL) was hydrogenated on a ParrShaker at 40 psi for 20 hours. The catalyst was removed by filtrationthrough celite. Evaporation and purification by flash chromatography(hexanes/ethyl acetate/methanol 6/3/1) gave a white foam solid (0.79 g,78% yield): MS m/s 403 (M+H)⁺; ¹H NMR (CDCl₃ 300 MHz) δ1.45 (s, 9 H),2.73 (m, 2 H), 3.41 (m, 4 H), 3.58 (m, 2 H), 3.86 (m, 2 H), 4.09 (m, 2H), 4.95 (br, 1 H), 6.60 (d, 2 H), 6.75 (m, 4 H), 6.93 (d, 2 H).

Step b) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, with one change, the compound waspurified by flash chromatography (hexanes/ethyl acetate/methanol 5/4/1)and was obtained as a light yellow solid (89% yield): MS mie 518 (M+H)⁺;¹H NMR (DMSO-d₆ 300 MHz) δ1.97 (s, 9 H), 3.27 (m, 1 H), 3.31 (m, 5 H),3.70 (m, 2 H), 3.89 (m, 1 H), 5.05 (m, 1 H), 6.48 (d, 1 H), 6.63 (d, 2H), 6.64 (d, 2 H), 6.70 (d, 2 H), 6.95 (m, 3 H), 8.87(s, 1 H), 12.16 (s,1 H).

Step c) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate and trifluoroaceticacid as described in example 1, step e, with modification, the productwas isolated as the free base, extracted from the aqueous layer withn-butanol and purified by flash chromatography (hexanes/ethylacetate/methanol 4/3/3) to give a white solid (20% yield): mp 165° C.;MS m/e 418 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.68 (m, 2 H), 2.71 (m, 1H), 2.97 (m, 3 H), 3.79 (d, 2 H), 3.98 (m, 1 H), 5.95 (d, 1 H), 6.58 (d,2 H), 6.64 (m, 1 H), 6.64 (d, 2 H), 6.67 (d, 1 H), 6.97 (d, 2 H), 8.94 (br, 1 H), other ¹H exchangeable are broad;

Analysis for C₂₀H₂₃N₃O₅ Calc'd: C, 57.54; H, 5.55; N, 10.07 Found: C,57.25; H, 5.41; N, 9.82.

EXAMPLE 6

5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxy-ethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (1 R)-2-[(4-Aminophenethyl)amino]-1-(3-chlorophenyl)-1-ethanol

This compound was prepared from (S)-3-chlorostyrene oxide and4-(2-aminoethyl)aniline as described in example 1, step b, withmodification, the mixture was stirred in tetrahydrofuran. The solventwas removed and the product was triturated in ethyl ether to give awhite solid (33% yield): MS m/e 291 (M+H )⁺; ¹H NMR (DMSO-d₆ 300 MHz)δ2.65 (m 3 H), 2.69 (m, 3 H), 4.62 (d, 1 H), 6.64 (d, 2 H), 6.99 (d, 2H), 7.26 (m, 3 H), 7.36 (s, 1 H), all ¹H exchangeable are broad;

Analysis for C₁₆H₁₉CIN₂O Calc'd: C, 66.09; H, 6.59; N, 9.63 Found: C,66.35; H, 6.73; N, 9.80.

Step b) tert-Butyl 4-aminophenethyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate.

This compound was prepared from (1R)-2-[(4-aminophenethyl)amino]-1-(3-chlorophenyl)-1-ethanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a colorless oil (78% yield):MS m/e 391 (M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.47 (s, 9 H), 2.63 (br, 2H), 3.16 (br, 1 H), 3.27 (d, 2 H), 3.41 (br, 1 H), 3.57 (s, 2 H), 4.64(br, 1 H), 4.82 (br,1 H), 6.62 (d, 2 H), 6.91 (d, 2 H), 7.23 (d, 3 H),7.34(d,1 H).

Step c) tert-Butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow foam solid(59% yield): MS m/e 506 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.31 (d, 9 H),2.59 (m, 2 H), 3.25 (m, 4 H), 4.72 (br, 1 H),5.56 (m, 1 H), 6.48 (d, 1H), 6.60 (d, 2 H), 7.01(m, 3 H), 7.33 (m, 4 H), 2.16 (br, 1 H).

Step d) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxy-ethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyi{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, with one modification, the product was isolated asthe free base, extracted from the aqueous layer with ethyl acetate andpurified by flash chromatography (dichloromethane/methanol/ammoniumhydroxide 9/0.99/0.01), and was obtained as a light yellow solid (25%yield): mp 162° C., MS m/e 406 (M+H); ¹H NMR (DMSO-d₆ 300 MHz) δ2.67 (m,2 H), 2.90 (m, 4 H), 4.74 (m, 1 H), 5.87 (br, H), 6.02 (d, 1 H), 6.56(d, 2 H), 6.99 (d, 2 H), 7.36 (m, 4 H), 7.98 (br, 1 H), otherexchangeable ¹H are broad.

Analysis for C₁₉H₂₀CIN₃O3S Calc'd: C, 56.22; H, 4.97,; N, 10.35 Found:C, 55.92; H, 4.99; N, 10.19.

EXAMPLE 7

5-[4-(2-{[(2R)-2-Hydroxy-2-phenylethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (1 R)-2-[(4-Aminophenethyl)amino]-1-phenyl-1-ethanol

This compound was prepared from (S)-styrene oxide and4-(2-aminoethyl)aniline, as described in example 1, step b, with onemodification, the mixture was reflux in tetrahydrofuran. The solvent wasremoved and the product triturated in ethyl ether to give a white solid(32% yield): MS m/e 257 (M+H )⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.67 (m 3 H),2.89 (m, 3 H), 3.57 (br, 2 H), 4.65 (m 1 H), 6.64 (d, 2 H), 6.99 (d, 2H), 7.27 (m, 1 H), 7.34 (m, 4 H), other ¹H exchangeable are broad.

Analysis for C₁₆H₂₀N₂O Calc'd: C, 74.97; H, 7.86; N, 10.93 Found: C,75.01; H, 7.58; N, 10.88.

Step b) tert-Butyl 4-aminophenethyl[(2R)-2-hydroxy-2-phenylethyl]carbamate

This compound was prepared from (1R)-2-[(4-aminophenethyl)amino]-1-phenyl-1-ethanol and di-tert-butyldicarbonate in substantially the same manner as described in example 1,step c, and was obtained as a colorless oil (88% % yield): MS mle 356(M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.32 (d, 9 H), 2.48 (m, 2 H), 3.22 (m, 4H), 4.67 (m, 1 H), 4.68 (s, 2 H), 5.40 (dd, 1 H), 6.46 (d, 2 H), 6.77(m, 2 H), 7.29 (m, 5 H).

Step c) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2R)-2-hydroxy-2-phenylethyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2R)-2-hydroxy-2-phenylethyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a light yellow solid(25% yield): MS m/e 471 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.32 (s, 9H),2.58 (m, 2 H), 3.25 (m, 3 H), 4.69 (m, 2 H), 5.40 (m, 1 H), 6.57 (d, 1H), 6.60 (d, 2 H), 6.97 (m, 3 H), 7.24 (m, 5 H), 12.15 (s, 1 H).

Step d) 5-[4-(2-{[(2R)-2-Hydroxy-2-phenylethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione.

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2R)-2-hydroxy-2-phenylethyl]carbamate and trifluoroacetic acid insubstantially the same manner as described in example 1, step e, and wasobtained as a yellow solid (52% yield): mp 55° C.; MS m/e 372 (M+H)⁺; ¹HNMR (DMSO-d₆ 300 MHz) δ2.90 (m, 2 H), 3.40 (m, 4 H), 3.60 (br, 1 H),4.90 (d, 1 H), 6.18 (br, 1 H),6.48 (d, 1 H), 6.65 (d, 2 H), 7.08 (d, 3H), 7.33 (m, 1 H), 7.39 (m, 4 H), 8.85 (br, 1 H),12.21 (br, 1 H);

Analysis for C₁₉H₂₁N₃O₃S×1.0 CF₃CO₂H Calc'd: C, 51.90; H, 4.57; N, 8.66Found: C, 51.21; H, 4.66; N, 8.34.

EXAMPLE 8

5-[4-(2-{[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-[(4-Fluorophenoxy)methyl]oxirane

This compound was prepared from 4-fluorophenol and (2S)(+)oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 1, step a, and was obtained as acolorless oil (80% yield): MS m/e 168 M⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.69(m, 1 H), 2.82 (m, 1 H), 3.30 (m, 1 H), 3.81 (m, 1 H), 4.30 (m, 1 H),6.97 (d, 2 H), 7.13 (d, 2 H).

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-(4-fluorophenoxy)-2-propanol

This compound was prepared from (2 S)-2-[(4-fluorophenoxy)methyl]oxiraneand 4-(2-aminoethyl)aniline as described in example 1, step b, with onemodification, the mixture was stirred at 70° c. in tetrahydrofuran. Thesolvent was removed in vacuo and the product was triturated with ethylether to give a white solid (51% yield): MS m/e 304 M⁺; ¹H NMR (CDCI₃300 MHz) δ1.22 (br 1 H), 2.71 (m, 3 H), 2.84 (m, 3 H), 3.40 (br, 1 H),3.57 (s, 2 H), 3.90 (m, 2 H), 3.99 (m, 1 H), 6.64 (d, 2 H), 6.83 (d, 2H), 6.95 (d, 4 H), 6.98 (d, 2 H);

Analysis for C₁₇H₂₁FN₂O₂Calc'd: C, 67.09; H, 6.96; N, 9.20 Found: C,66.80; H, 7.02, N, 9.12.

Step c) tert-Butyl 4-aminophenethyl[(2 S)-3-(4-fl uorophenoxy)-2-hydroxypropyl]carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-(4-fluorophenoxy)-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a colorless oil (76% yield):MS mle 405 (M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.45 (s, 9 H), 2.71 (m, 2 H),3.41 (m, 4 H), 3.57 (m, 2 H), 3.82 (m, 1 H), 3.84 (m, 1 H), 4.07 (m, 2H), 6.62 (d, 2 H), 6.82 (d, 2 H), 6.94 (m, 4 H);

Analysis for C₂₂H₂₉FN₂O₄ Calc'd: C, 65.33; H, 7.23; N, 6.93 Found: C,6.93; H, 7.24; N, 6.72.

Step d) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-3-(4-fluorophenoxy)-2-hydroxypropyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-3-(4-fluorophenoxy)-2-hydroxypropyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (69%yield): MS m/e 519 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.28 (s, 9 H), 2.85(br, 1 H), 3.08 (br, 1 H), 3.31 (m, 4H), 3.78 (m, 2 H),3.82 (m, 1 H),6.40 (s, 1 H), 6.59 (d, 2 H), 6.88 (d, 2 H), 6.97 (d, 2 H), 7.04 (d, 2H), all ¹H exchangeable are broad.

Step e) 5-[4-(2-{[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-3-(4-fluorophenoxy)-2-hydroxypropyl]carbamate and trifluoroaceticacid in substantially the same manner as described in example 1, step e,and was obtained as a yellow solid (90%): mp 55° C.; MS m/e 420 (M+H)⁺;¹H NMR (DMSO-d₆ 300 MHz) δ2.81 (m, 2 H), 3.03 (m, 1 H), 3.20 (m, 2 H),3.95 (m, 2 H), 4.01 (m, 1 H), 6.48 (s, 1 H), 6.63 (d, 2 H), 6.96 (d, 2H), 7.07 (m, 4 H), all ¹H exchangeable are broad.

Analysis for C₂₀H₂₂FN₃O₄S×1 CF₃COOH×1.39 H₂O Calc'd: C, 47.26; H, 4.43;N, 7.52 Found: C, 47.04; H, 4.18; N, 7.02.

EXAMPLE 9

5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-(Phenoxymethyl)oxirane

This compound was prepared from phenol and (2 S)(+)oxiranylmethyl3-nitrobenzenesulfonate in substantially the same manner as described inexample 1, step a, and was obtained a colorless oil (73% yield): MS m/e150 M⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.69 (m, 1 H), 2.82 (m, 1 H), 3.31 (m,1 H), 3.81 (m, 1 H), 4.28 (m, 1 H), 6.95 (m, 3 H), 7.27 (m, 2 H).

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-phenoxy-2-propanol

This compound was prepared from (2 S)-2-(phenoxymethyl)oxirane and4-(2-aminoethyl)aniline as described in example 1, step b, with onemodification, the mixture was stirred at 70° C. in tetrahydrofuran. Thesolvent was removed in vacuo and the product was triturated with ethylether to give a white solid (46% yield): MS m/e 286 M⁺, ¹H NMR (CDCI₃300 MHz) δ1.54 (br 1 H), 2.70 (m, 3 H), 2.85 (m, 3 H), 3.40 (br, 1 H),3.57 (s, 2 H), 3.96 (m, 2 H), 4.01 (m, 1 H), 6.64 (d, 2 H), 6.88 (d, 2H), 6.90 (m, 3 H), 7.25 (m, 2 H);

Analysis for C₁₇H₂₂N₂O₂ Calc'd: C, 71.30; H, 7.74; N, 9.78 Found: C,70.83; H, 7.72; N, 9.83.

Step c) tert-Butyl 4-aminophenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-phenoxy-2-propanol and di-tert-butyldicarbonate in substantially the same manner as described in example 1,step c, and was obtained as a colorless oil (84% yield): MS mle 387(M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.46 (s, 9 H), 2.71 (m, 2 H), 3.41 (m, 4H), 3.57 (m, 2 H), 3.88 (m, 1 H), 3.96 (m, 1 H), 4.09 (m, 2 H), 6.62 (d,2 H), 6.96 (d, 2 H), 6.97 (m, 3 H), 7.25 (m, 2 H);

Analysis for C₂₂H₃₀N₂O₄ Calc'd: C, 68.37; H, 7.82; N, 7.25 Found: C,68.08; H, 7.76; N, 6.76.

Step d) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (69%yield); MS m/e 502 M⁺; H NMR (DMSO-d₆ 300 MHz) δ1.33 (s, 9 H), 3.01 (br,1 H), 3.08 (br, 1 H), 3.31 (m, 5 H), 3.82 (m, 2 H), 3.89 (m, 1 H), 5.12(m, 1 H), 6.49 (d, 1 H), 6.60 (d, 2 H), 6.88 (d, 2 H), 6.98 (m, 3 H),7.28 (m, 2 H),12.16 (s, 1 H).

Step e) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate and trifluoroacetic acid insubstantially the same manner as described in example 1, step e, and wasobtained as a yellow solid (90% yield): mp 55° C.; MS m/e 420 (M+H)⁺; ¹HNMR (DMSO-d₆ 300 MHz) δ2.81 (m, 3 H), 3.98 (m, 2 H), 4.15 (m, 1 H), 3.98(m, 2 H), 4.15 (m, 1 H), 5.86 (br, 1 H) 6.50 (d, 1 H), 6.63 (d, 2 H),6.96 (m, 3 H), 7.09 (m, 3 H), 7.29, (m, 2 H), 8.60 (br, 2 H), 12.21 (br,1 H);

Analysis for C₂₀H₂₃N₃O₄S×1 CF₃COOH×0.84 H₂O Calc'd: C, 49.75; H, 4.83;N, 7.91 Found: C, 49.07; H, 4.38; N, 7.33.

EXAMPLE 10

5-[4-(2-{[(2S)-2-Hydroxy-3-(4-methoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-[(4-Methoxyphenoxy)methyl]oxirane

This compound was prepared from 4-methoxyphenol and (2S)(+)oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 1, step a, and was obtained as acolorless oil (64% yield): MS m/e 180 M⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.78(m, 1 H) 2.85 (m, 1 H), 3.38 (m, 1 H), 3.71 (m, 3 H), 3.80 (m, 1 H),4.25 (m, 1 H), 6.98 (m, 4 H).

Step b) (2S)-1-[(4-Aminophenethyl)amino]-3-(4-methoxyphenoxy)-2-propanol

This compound was prepared from (2S)-2-[(4-methoxyphenoxy)methyl]oxirane and 4-(2-aminoethyl)aniline asdescribed in example 1, step b, with one modification, the mixture wasstirred at 70° C. in tetrahydrofuran. The solvent was removed in vacuoand the product was triturated with ethyl ether to give a white solid(67% yield): mp 60° C., MS m/e 317 (M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.60(br, 2 H), 2.75 (m, 3 H), 2.85 (m, 3 H), 3.58 (br, 2 H), 3.76 (s, 3 H),3.88 (m, 2 H), 4.00 (m, 1 H), 6.65 (d, 2 H), 6.82 (s, 4 H), 6.99 (d, 2H);

Analysis for C₁₈H₂₄N₂O₃ Calc'd: C, 68.33; H, 7.65; N, 8.85 Found: C,68.07; H, 7.61; N, 9.13.

Step c) tert-Butyl ⁴-aminophenethyl[(2 S)-2-hydroxy-3-(4-methoxyphenoxy)propyl]carba mate

This compound was prepared from (2S)-1-[(⁴-aminophenethyl)amino]-3-(4-methoxyphenoxy)-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a colorless oil (57% yield):MS m/e 416 (M+H)⁺,; ¹H NMR (CDCI₃ 300 MHz) δ1.45 (s, 9 H), 2.71 (m, 2H), 3.44 (m, 4 H), 3.57 (br, 2 H), 3.76 (s, 3 H), 3.81 (m, 1 H), 3.82(m, 1 H), 4.08 (m, 2 H), 6.62 (d, 2 H), 6.91 (s, 4 H), 6.93 (d, 2 H);

Analysis for C₂₃H₃₂N₂O₅ Calc'd: C, 66.32; H, 7.74; N, 6.72 Found: C,66.18; H, 7.75; N, 6.64.

Step d) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-methoxyphenoxy)propyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-2-hydroxy-3-(4-methoxyphenoxy)propyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (60%yield); MS mle 532 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.33 (s, 9 H), 3.08(br, 1 H), 3.38 (m, 4 H), 3.75 (s, 3 H), 3.76 (m, 1 H), 3.92 (m, 1 H),5.10 (m, 1 H), 6.45 (d, 1 H), 6.61 (d, 2 H), 6.83 (s, 4 H), 6.99 (d, 2H), 12.16 (s, 1 H), other ¹H exchangeable are broad;

Analysis for C₂₆H₃₃N₃O₇S Calc'd: C, 58.74; H, 6.26; N, 7.90 Found: C,58.10; H, 6.33; N, 8.40.

Step e) ⁵-[⁴-(2-{[(2 S)-2-Hydroxy-3-(4-methoxyphenoxy)propyl]amino}ethyl) anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(4-methoxyphenoxy)propyl]carbamate and trifluoroaceticacid in substantially the same manner as described in example 1, step e,and was obtained as a light yellow solid (60% yield): mp 56° C.; MS m/e432 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.87 (m, 2 H), 3.17(m, 1 H), 3.19(m, 3 H), 3.70 (s, 3 H), 3.90 (br 2 H), 4.13 (br, 1 H) 5.87 (d, 1 H),6.65 (d, 1 H), 6.67 (d, 2 H), 6.88 (s, 4 H), 7.08 (m, 3 H), 8.58 (br, 2H), 12.21 (br, 1 H);

Analysis for C₂₁H₂₅N₃O₅S×1CF₃COOH×0.78 H₂O Calc'd: C, 49.37; H, 4.96; N,7.51 Found: C, 48.35; H, 4.33; N, 7.02.

EXAMPLE 11

5-{⁴-[2-({(2S)-3-[3-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

Step a) (2 S)-2-{[3-(Benzyloxy)phenoxy]methyl}oxirane

This compound was prepared from 3-benzyloxyphenol and (2S)(+)oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 1, step a, and was obtained as acolorless oil (47% yield): MS m/e 256 M⁺; ¹H NMR (DMSO-d₆ 300 MHz),δ2.67 (m, 1 H) 2.80 (m, 1 H), 3.30 (m, 1 H), 3.80 (m, 3 H), 4.27 (m, 1H), 5.07 (s, 2 H), 6.54 (m, 1 H), 6.60 (m, 2 H), 7.19 (m, 1 H), 7.39 (m,5 H).

Step b) (2S)-1-[(4-Aminophenethyl)amino]-3-[3-(benzyloxy)phenoxy]-2-propanol

This compound was prepared from (2S)-2-{[3-(benzyloxy)phenoxy]methyl}oxirane and 4-(2-aminoethyl)anilineas described in example 1, step b, with one modification, the mixturewas stirred at 70° C. in tetrahydrofuran. The solvent was removed undervacuo and the product was triturated with ethyl ether to give a whitesolid (67% yield): MS m/e 392 M⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.6 (br, 1 H),2.69 (m, 3 H), 2.85 (m, 3 H), 3.30 (br, 1 H), 3.55 (s, 2 H), 3.92 (m, 2H), 4.00 (m, 1 H), 5.03 (s, 2 H), 6.59 (m, 5 H), 7.00 (d, 2 H), 7.19 (t,1 H), 7.40 (m, 5 H);

Analysis for C₂₄H₂₈N₂O₃ Calc'd: C, 73.44; H, 7.19; N, 7.14 Found: C,73.12; H, 7.06; N, 7.15.

Step c) tert-Butyl 4-aminophenethyl{(2S)-3-[3-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-[3-(benzyloxy)phenoxy]-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a light yellow oil (57%yield): MS m/e 493 (M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.58 (s, 9 H), 2.71(m, 2 H), 3.41 (m, 4 H), 3.55 (br, 2 H), 3.84 (br, 1 H), 3.92 (br, 1 H),4.09 (m, 2 H), 5.04 (s, 2 H), 6.59 (m, 5 H), 6.93 (d, 2 H), 7.19 (t, 1H), 7.38 (m, 5 H);

Analysis for C₂₉H₃₆N₂O₅ Calc'd: C, 70.71; H, 7.37; N, 5.69 Found: C,69.95; H, 7.20; N,5.40.

Step d) tert-Butyl (2S)-3-[3-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl{(2S)-3-[3-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (83%yield): MS m/e 608 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.33 (s, 9 H), 2.64(m, 2 H), 3.27 (br, 1 H), 3.34 (m, 3 H), 3.82 (m, 2 H), 3.93 (m, 1 H),5.06 (s, 2 H), 5.12 (m, 1 H), 6.49 (m, 6 H), 6.99 (m, 2 H), 7.17 (t, 1H), 7.38 (m, 6 H), 12.16 (s, 1 H);

Analysis for C₃₂H₃₇N₃O₇S Calc'd: C, 63.24; H, 6.14; N, 6.91 Found: C,62.50; H, 6.33; N, 7.15.

Step e ) 5-{4-[2-({(2S)-3-[3-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2S)-3-[3-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, and was obtained as a light yellow solid (23%yield): mp 53° C.; MS m/e 508 (M+H)⁺,; ¹H NMR (DMSO-d₆ 300 MHz) δ2.86(m, 2 H), 3.06 (m, 2 H), 3.20 (m, 3 H), 3.96 (s, 2 H), 4.15 (br 1 H),5.09 (s, 2 H) 5.98 (br, 1 H), 6.59 (m, 5 H), 7.07 (m, 2 H), 7.20 (t,1H), 7.43 (m, 5 H), 8.58 (br, 2 H), 12.21 (br, 1 H);

Analysis for C₂₇H₂₉N₃O₅S×1 CF₃COOH×0.97 H₂O Calc'd: C, 54.50; H, 45.04;N, 6.76 Found: C, 54.13; H, 5.02; N, 6.10.

EXAMPLE 12

5-[4-(2-{[(2S)-2-Hydroxy-3-(3-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) tert-butyl 4-aminophenethyl[(2 S)-2-hydroxy-3-(3-hydroxyphenoxy)propyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl{(2S)-3-[3-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate in substantiallythe same manner as described in example 5, step a, and was obtained as awhite solid (73% yield): MS m/s 403 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz)δ1.36 (s, 9 H),2 .58 (t, 2 H), 3.07(m, 1 H), 3.28 (m, 3 H), 3.74 (m, 2H), 4.83 (s, 2 H), 5.07 (br, 1 H), 4.95 (br,1 H), 6.32 (m, 3 H), 6.45(d, 2 H), 6.80 (d, 2 H), 7.02 (t,1 H), 9.34 (s,1 H).

Step b) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(3-hydroxyphenoxy)propyl]carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-2-hydroxy-3-(3-hydroxyphenoxy)propyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (89%yield): MS m/e 518 (M+H)⁺; H NMR (DMSO-d₆ 300 MHz) δ1.35 (s, 9 H), 3.01(br, 1 H), 3.31 m, 2 H), 3.76 (m, 2 H), 3.94 (m, 1 H), 5.11 (br, 1 H),6.32 (m, 3 H), 6.50 (d, 1 H), 6.62 (d, 2 H), 7.03 (m, 4 H), 9.36 (s, 1H), 12.18 (s, 1 H).

Step c) 5-[4-(2-{[(2S)-2-Hydroxy-3-(3-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl[(2S)-2-hydroxy-3-(3-hydroxyphenoxy)propyl]carbamate and trifluoroaceticacid as described in example 1, step e, with one change, he product waspurified by reverse HPLC to give an off white solid (22% yield): mp 65°C.; MS m/ 418 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.82 (m, 2 H), 3.05 (m,1 H), 3.20 (m, 3 H), 3.89 (m, 2 H), 4.14 (br 1 H), 5.87 (s, 1 H), 6.36(m, 3 H), 6.49 (d, 1 H), 6.66 (d, 2 H), 7.08 (m, 4 H), 8.59 (s, 2 H),9.48 (s, 1 H), 12.21 (s, 1 H); Analysis for C₂₀H₂₃N₃O₅S×1 CF₃COOH×2.47H₂O Calc'd: C, 45.83, H, 5.03,, N, 7.29 Found: C, 45.03, H, 4.37, N,7.24.

EXAMPLE 13

5-[4-(2-{[(2 S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2 S)-1-[(4-Aminophenethyl)amino]-3-(9H-carbazol-4-yloxy)-2-propanol

This compound was prepared from 9 H-carbazol-4-yl (2 S)oxiranylmethylether and 4-(2-aminoethyl)aniline as described in example 1, step b,with one change, the product was purified by flash chromatography(dichloromethane/methanol 9.5/0.5) and recrystallized fromtetrahydrofuran/toluene to give an off white solid (67% yield): MS m/e376 (M +H)⁺,; ¹H NMR (CDCI₃ 300 MHz) δ1.80 (br, 1 H), 2.71 (m, 2 H),2.90 (m, 3 H), 3.06 (m, 1 H), 3.55 (br, 2 H), 4.22 (m, 3 H), 6.60 (d, 2H), 6.61 (d, 1 H), -p0--p7.01 (d, 2 H), 7.25 (d, 1 H), 7.26 (m, 5 H),8.09 (s, 1 H), 8.26( s, 1 H);

Analysis for C₂₃H₂₅N₃O₂ Calc'd: C, 73.57; H, 6.71; N, 11.19 Found: C,73.41; H, 6.82; N, 11.00.

Step b) tert-Butyl 4-aminophenethyl[(2 S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-(9H-carbazol-4-yloxy)-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a white shiny solid (56%yield): MS m/e 476 (M+H)⁺; ¹H NMR (DMSO d₆ 300 MHz) δ1.35 (s, 9 H), 2.50(m, 2 H), 3.28 (m, 3 H), 3.49 (dd, 1 H), 4.08 (m, 2 H), 4.14 (m, 1 H),4.81 (s, 2 H), 5.25 (d, 1 H), 6.41 (d, 2 H), 6.64 (d, 1 H), 6.69 (m, 2H), 7.04 (d, 1 H), 7.06 (t, 1 H), 7.24, (t, 1 H), 7.26 (t, 1 H), 7.28(d, 1 H), 8.30 (dd, 1 H), 11.22 (s, 1 H); Analysis for C₂₈H₃₃N₃O₄Calc'd: C, 70.71; H, 6.99; N, 8.84 Found: C, 69.94; H, 7.39; N, 8.57.

Step c) tert-Butyl (2 S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2 S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (50 %yield): MS m/e 591 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.35 (s, 9 H), 2.66(t, 2 H), 3.28 (m, 2 H), 3.31 m, 2 H), 3.39 (m, 2 H), 4.10 (m, 2 H),4.20 (m, 1 H), 5.29, (d, 2 H), 6.45 (d, 1 H), 6.57 (d, 2 H), 6.64 (d, 1H), 6.98 (m, 2 H), 7.06 (d, 1 H), 7.08 (t, 1 H), 7.26 (t, 1 H), 7.28 (t,1 H), 7.44 (d, 1 H), 8.31 (m, 1 H), 11.24 (s, 1 H), 12.17 (s 1 H).

Step d) 5-[4-(2-{[(2 S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2 S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, to give an off white solid (22% yield): mp 140°C.; MS m/e 491 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.48 (m, 2 H), 3.21 (m,3 H), 3.40 (m, 2 H), 4.20 (m, 2 H), 4.38 (br, 1 H), 6.01 (br, 1 H), 6.47(d, 1 H), 6.63 (m, 3 H), 7.08 (m, 4 H), 7.35 (m, 2 H), 7.43 (d, 1 H),8.21 (d, 1 H), 8.66 (br, 2 H), 11.28 (s, 1 H), 12.21 (s, 1 H);

Analysis for C₂₆H₂₆N₄O₄S×1 CF₃COOH×1 H₂O Calc'd: C, 55.63; H, 4.80; N,10,23 Found: C, 55.77; H, 4.81; N, 8.92.

EXAMPLE 14

N{5-[(1S)-2-({4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide

Step a) N[2-(Benzyloxy)-5-((1S)-2-bromo-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl]methanesulfonamide

A solution of tert-butyldimethylsilyl triflate (11.25 mL, 5.41 mmol) indichloromethane (10 mL) was added slowly into a cold (−78° C.) mixtureof N-{2-(benzyloxy)-5-[(1S)-2-bromo-1-hydroxyethyl]phenyl}methanesulfonamide (1.93 g, 4.82 mmol),2,6 lutidine (1.08 mL, 9.64 mmol) and dichloromethane(30 mL). The newmixture was warmed up to room temperature, stirred for 4 hours, pouredinto a saturated aqueous bicarbonate solution, and extracted with ethylether. The organic extracts were washed with brine, and dried overMgSO₄. Evaporation and purification by flash chromatography(hexanes/ethyl acetate 9/1) gave a white solid (1.55 g, 62% yield): MSm/e 513 M⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.10 (s, 3 H), 0.16 (s, 3 H),0.84(s, 9 H), 2.88 (s, 3 H), 3.56 (m, 2 H), 4.88 (m, 1 H), 5.14 (s, 2H), 7.11 (d, 1 H), 7.16 (d, 1 H), 7.32 (m, 2 H), 7.38 (m, 2 H), 7.51 (d,2 H), 8.90 (s, 1 H);

Analysis for C₂₄H₂₉N₃O₄S Calc'd: C, 51.35, H, 6.27, N, 2.72 Found: C,50.02, H, 6.27, N, 2.53.

Step b) N-[5-((1 S)-2-[(4-Aminophenethyl)amino]-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-2-(benzyloxy)phenyl]methanesulfonamide

A mixture of N-[2-(benzyloxy)-5-((1S)-2-bromo-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl]methanesulfonamide(1.55 g, 3.012 mmol), 4-(2-aminoethyl)aniline (0.53 g, 3.915 mmol),diisopropyl amine (2.4 ml, 19.60 mmol), sodium iodide (0.04 g) andtetrahydrofuran ( 5 mL) was stirred in a sealed flask at 100° C. for 48hours. The mixture was cooled to room temperature, diluted with ethylacetate, washed with aqueous brine solution, and dried over MgSO₄.Evaporation and purification by flash chromatography (hexanes/ethylacetate/methanol/triethylamine 7/2/0.95/0.05) gave a white solid (1.25g, 72%): MS m/e 371 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.10 (s, 3 H),0.16 (s, 3 H), 0.84 (s, 9 H), 2.65 (m, 6 H), 2.83 (s, 3 H), 4.65 (m, 1H), 4.80 (s, 2 H), 5.18 (s, 2 H), 6.42 (d, 2 H), 6.80 (d, 2 H), 7.15 (s,2 H), 7.21 (s, 1 H), 7.35 (m, 4 H), 7.50 (d, 2 H), 8.8 ( br, 1 H);

Analysis for C₂₉H₄₃N₃O₄ SSi Calc'd: C, 63.18; H, 7.54; N, 7.37 Found: C,62.41; H, 7.45; N, 7.11.

Step c) N-[5-{(1S)-2-[(4-Aminophenethyl)amino]-1-[(triethylsilyl)oxy]ethyl}-2-(benzyloxy)phenyl]methanesulfonamide

This compound was prepared from N-(2-(benzyloxy)-5-{2-iodo-1-[(triethylsilyl)oxy]ethyl}phenyl)methanesulfonamide and4-(2-aminoethyl)aniline, as described in example 1, step b, without thepresent of sodium iodide to give a white solid (79% yield): MS m/e 570(M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.77 (m, 6 H), 0.79 (m, 9 H), 2.64 (m,6 H), 2.84 (s, 3 H), 4.65 (m, 1 H), 4.80 (d, 2 H),5.13 (s, 2 H), 6.44(d, 2 H), 6.79 (d, 2 H) 7.06 (m, 3 H), 7.24 (s, 1 H), 7.25 (m, 1 H),7.38 (m, 2 H), 7.51 (d, 2 H), 8.40 ( br, 1 H);

Analysis for C₃₀H₄₃N₃O SSi Calc'd: C, 63.18; H, 7.54; N, 7.37 Found: C,62.20; H, 7.39; N, 7.30.

Step d) N-[5-{(1S)-2-[(4-Aminophenethyl)amino]-1-hydroxyethyl}-2-(benzyloxy)phenyl]methanesulfonamide

A mixture of N-[5-{(1S)-2-[(4-aminophenethyl)amino]-1-[(triethylsilyl)oxy]ethyl)-2-(benzyloxy)phenyl]methanesulfonamide(2.2 g, 4.28 mmol), tetrabutylammonium fluoride: 1.0 M solution intetrahydrofuran (20 ml) and terahydrofuran (15 ml) was stirred atambient temperature for 48 hours, poured into water, basified withsaturated bicarbonate solution, and extracted with ethyl acetate. Theorganic extracts were washed with aqueous brine solution, and dried overMgSO₄. Evaporation and recrystallization from ethyl acetate gave a whitesolid (1.5 g, 78% yield): MS m/e 456 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz)δ2.65 (m, 6 H), 2.83 (s, 3 H), 3.18 (m, 1 H), 4.65 (m, 1 H), 4.80 (s, 2H), 5.18 (s, 2 H), 5.20 (m, 1 H), 6.42 (d, 2 H), 6.80 (d, 2 H), 7.15 (m,2 H), 7.21 (s, 1 H), 7.35 (m, 1 H), 7.41 (t, 2 H),7.56 (d, 2 H), 8.30 (br, 1 H);

Analysis for C₂₄H₂₉N₃O₄ S Calc'd: C, 63.22; H, 6.36; N, 9.22 Found: C,62.57; H, 6.55; N, 8.81.

Step e) N-(5-{(1S)-2-[(4-Aminophenethyl)amino]-1-hydroxyethyl}-2-hydroxyphenyl)methanesulfonamide

This compound was prepared from N-[5-{(1S)-2-[(4-aminophenethyl)amino]-1-hydroxyethyl}-2-(benzyloxy)phenyl]methanesulfonamidein substantially the same manner, as described in example 2, step a,with one change; the compound was recrystallized from ethanol and ethylacetate to give a white solid (80% yield): MS m/s 366 (M+H)⁺; ¹H NMR(DMSO d₆ 300 MHz) δ2.48 (m, 2 H), 2.59 (d, 2 H), 2.67 (m, 2 H), 2.89 (s,3 H), 4.45 (t, 1 H), 4.79 (s, 2 H), 6.44 (d, 2 H), 6.82 (m, 3 H), 6.93(d, 2 H), 7.13 (s, 1 H), all ¹H exchangeable are broad.

Step f) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl((2S)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)carbamate

This compound was prepared from N-(5-{(1S)-2-[(4-aminophenethyl)amino]-1-hydroxyethyl}-2-hydroxyphenyl)methanesulfonamideand di-tert-butyl dicarbonate in substantially the same manner asdescribed in example 1, step c, and was obtained as an off white solid(64% yield): MS m/e 466 (M+H)⁺; ¹H NMR (DMSO d₆ 300 MHz) δ1.35 (s, 9 H),2.88 (s, 3 H), 3.01 (m, 2 H), 3.03 (m, 2 H), 4.57 (m, 1 H), 4.81 (s, 2H), 5.30 (dd, 1 H), 6.45 (d, 2 H), 6.80 (m, 1 H), 6.82 (d, 2 H), 6.94(t, 1 H), 7.13 (s, 1 H), 8.59 (s, 1 H), 9.69 (s, 1 H).

Step g) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yI)amino]phenethyl((2S)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)carbamate

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl((2S)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)carbamateand 5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manneras described in example 1, step d, and was obtained as a yellow solid(46% yield): MS m/e 581 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.35 (d, 9 H),2.49 (m, 2 H), 2.88 (s, 3 H), 3.27 (m, 4 H), 4.59 (m, 1 H), 5.28 (dd, 1H), 6.47 (d, 1 H), 6.59, (d, 2 H), 6.84 (m, 1 H), 6.96 (m, 3 H), 7.14(t, 1 H), 7.23 (m, 1 H), 8.61 (s, 1 H), 9.71 (s, 1 H), 12.23 (s, 1 H).

Step h) N-{5-[(1S)-2-({4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl((2S)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, to give an off white solid (22% yield): mp 130°C.; MS m/e 481 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.83 (m, 2 H), 2.95 (m,3 H), 3.09 (m, 1 H), 3.10 (br, 3 H), 4.78 (d, 1 H), 6.7 (s, 1 H), 6.47(d, 1 H), 6.65 (d, 2 H), 6.89 (d, 1 H), 7.05 (m, 4 H), 7.23 (s, 1 H),8.57 (br, 2 H), 8.74 (s, 1 H), 9.96 (s, 1 H), 12.20 (s, 1 H);

Analysis for C₂₀H₂₄N₄O₆S₂×1 CF₃COOH×1.87 H₂O Calc'd: C, 55.63; H, 4.80;N, 10,23 Found: C, 55.77; H, 4.81, N, 8.92.

EXAMPLE 15

5-[4-(2-{[(2S)-3-(1-Benzofuran-5-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) 4-Hydroxybenzofuran.

A solution of boron tribromide: 1.0 M solution in methylene chloride (95ml) was added slowly into a cold (−78° C.) solution of5-methoxybezofuran (10 g, 67.5 mmol) in dichloromethane(100 mL). The newmixture was warmed up to room temperature, stirred for 18 hours, pouredinto a saturated aqueous bicarbonate solution, and extracted with ethylacetate. The organic extracts were washed with brine, dried over MgSO₄.Evaporation and purification by flash chromatography (hexanes/ethylacetate 9/1) gave a white solid (5.9 g, 65%): MS m/e 133 (M−H)⁺; ¹H NMR(DMSO-d₆ 300 MHz) δ6.72 (m, 1 H), 6.78 (d, 1 H), 6.94 (d, 1 H), 7.35 (d,1), 781, (s, 1 H), 8.18 (s, 1 H).

Step b) 1-Benzofuran-5-yl (2 R)-oxiranylmethyl ether

This compound was prepared from 4-hydroxybenzofuran and (2S)-(+)oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 1, step a, and was obtained as colorlessoil (38% yield): MS m/e 190 (M )⁺,; ¹H NMR (DMSO-d₆ 300 MHz): δ2.71 (m,1 H) 2.85 (m, 1 H), 3.34 (m, 1 H), 3.85 (m, 1 H), 4.33 (m, 1 H), 6.88(s, 1 H), 6.94 (d, 1 H), 7.16 (s, 1 H), 7.48 (d, 1 H), 7.94 (s, 1 H).

Step c) (2 S)-1 -[(4-Aminophenethyl)amino]-3-(1-benzofuran-5-yloxy)-2-propanol

This compound was prepared from 1-benzofuran-5-yl (2 R)oxiranylmethylether and 4-(2-aminoethyl)aniline as described in example 1, step b,with one modification, the mixture was stirred at 70° C. intetrahydrofuran for 48 hours. The solvent was removed in vacuo and theproduct was triturated with ethyl ether to give a white solid (25%yield): MS m/e 326 M⁺; ¹H NMR (CDCI₃ 300 MHz) δ2.61 (br, 1 H), 2.83 (m,6 H), 3.57 (s, 3 H), 4.01 (m, 3 H), 6.63 (m, 2 H), 6.65 (s, 1 H), 6.88(m, 1 H), 6.98 (m, 2 H), 7.00 (m, 1 H), 7.25 (d, 1 H), 7.39 (s, 1 H);

Analysis for C₁₉H₂₂N₂O₃ Calc'd: C, 69.92; H, 6.79; N, 8.58 Found: C,69.74; H, 6.77; N, 9.10.

Step d) tert-Butyl 4-aminophenethyl[(2S)-3-(1-benzofuran-5-yloxy)-2-hydroxypropyl]carbamate

This compound was prepared (2S)-1-[(4-aminophenethyl)amino]-3-(1-benzofuran-5-yloxy)-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a light yellow oil (48%yield): MS m/e 426 (M)⁺; ¹H NMR (CDCI₃ 300 MHz) δ1.44 (s, 9 H), 2.72 (m,2 H), 3.44 (m, 4 H), 3.60 (br, 2 H), 3.90 (br, 1 H),3.98 (br, 1 H), 4.09(m, 2 H), 6.60 (m, 2 H), 6.70 (s, 1 H), 6.92 (m 3 H), 7.05 (s, 1 H),7.40 (d, 1 H), 7.60 (s,1 h).

Step e) tert-Butyl (2 S)-3-(1-benzoturan-5-yloxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-3-(1-benzofuran-5-yloxy)-2-hydroxypropyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as yellow solid (50%yield), MS m/e 591 (M+H)⁺, ¹H NMR (DMSO-d₆ 300 MHz) δ1.35 (s, 9 H), 2.66(m, 3 H), 3.40 (m, 3 H), 3.98 (m, 3 H), 5.14 (br, 1 H), 6.59 (d, 2 H),6.61 (d, 1 H), 6.85 (m, 2 H), 6.99 (m, 3 H), 7.13 (s, 1 H), 7.45 (d, 1H),7.91 (s, 1 H), 12.16 (br, 1 H).

Step f) 5-[4-(2-{[(2S)-3-(1-Benzofuran-5-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2S)-3-(1-benzofuran-5-yloxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid as described in example 1, step e, with onechange, the product was purified by reverse HPLC to give an off whitesolid (10% yield): mp 50° C.; MS m/e 442 (M+H)⁺; ¹H NMR (DMSO-d₆ 300MHz) δ2.86 (m, 2 H), 3.23 (m, 4 H), 3.99 (m, 2 H), 4.16 (m, 1 H), 5.85(br, 1 H), 6.48 (d, 1 H), 6.65 (d, 2 H), 6.87 (m, 2 H), 7.07 (m, 3 H),7.18 (s, 1 H), 7.48 (d, 1 H), 7.94 (s, 1 H), 8.60 (br, 2 H), 12.20 (s, 1H);

Analysis for C₂₂H₂₃N₃O₅S×1.3 CF₃COOH×1.25 H₂O Calc'd: C, 48.21; H, 4.16;N, 6.86 Found: C, 46.44; H, 4.16; N, 6.86.

EXAMPLE 16

5-[4-(2-{[(2S)-3-(4-Butoxyphenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (2F)-2-[(4-Butoxyphenoxy)methyl]oxirane

This compound was prepared from 4-butoxyphenol and (2S)-(+)oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 1, step a, and was obtained as acolorless oil (51% yield): MS m/e 222 M⁺; ¹H NMR (DMSO-d₆ 300 MHz):δ0.90 (t, 3 H), 1.41 (m, 2 H), 1.64 (m, 2 H), 2.65 (m, 1 H), 2.80 (m, 1H), 3.29 (m, 1 H), 3.75 (m, 1 H), 3.85 (t, 2 H), 4.24 (dd, 1 H), 6.87(dd, 4 H);

Analysis for C₁₃H₁₈O₃ Calc'd: C, 70.25; H, 8.16 Found: C, 69.94 H, 8.13.

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-(4-butoxyphenoxy)-2-propanol

This compound was prepared from (2 R)-2-[(4-butoxyphenoxy)methyl]oxiraneand 4-(2-aminoethyl)aniline as described in example 1, step b, with onemodification, the mixture was stirred at 70° C. in tetrahydrofuran for48 hours. The solvent was removed in vacuo and the product wastriturated with ethyl ether to give a white solid (49% yield): MS m/e286 (M)⁺; ¹H NMR (CDCI₃ 300 MHz) δ0.96 (t, 3 H) 1.46 (m, 2 H), 1.75 (m,2 H), 1.85 (br, 1 H), 2.69 (m, 3 H), 2.82 (m, 3 H), 3.57 (br, 2 H), 3.88(m, 5 H), 3.98 (m, 1 H), 6.61 (d, 2 H), 6.81 (s, 4 H), 6.99 (d, 2 H);Analysis for C₂₁H₃₀N₂O₃ Calc'd: C, 70.29; H, 7.79; N, 7.81 Found: C,70.20; H, 8.32; N, 7.86.

Step c) tert-Butyl 4-aminophenethyl[(2S)-3-(4-butoxyphenoxy)-2-hydroxypropyl]carbamate

This compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-(4-butoxyphenoxy)-2-propanol anddi-tert-butyl dicarbonate in substantially the same manner as describedin example 1, step c, and was obtained as a colorless oil (66% yield),MS m/e 459 (M+H)⁺; ¹H NMR (CDCI₃ 300 MHz) δ0.96 (t, 3 H), 1.45 (s, 9 H),1.46 (m, 2 H), 1.74 (m, 2 H), 2.70 (m, 2 H), 3.39 (m, 4 H), 3.57 (br, 2H), 3.88 (m, 1 H), 3.90 (m, 3 H), 4.09 (br, 2 H), 6.60 (d, 2 H), 6.81(s, 4 H), 6.93 (d, 2 H);

Analysis for C₂₆H₃₈N₂O₅×0.6 C₄H₈O₂ Calc'd: C, 66.66; H, 7.68; N, 5.66Found: C, 65.32; H, 7.95; N, 5.69.

Step d) tert-Butyl (2S)-3-(4-butoxyphenoxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl[(2S)-3-(4-butoxyphenoxy)-2-hydroxypropyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a light yellow solid(63% yield): MS m/e 573 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.93 (t, 3 H),1.35(s, 9 H), 1.42 (m, 2 H), 1.67 (m, 2 H), 2.65 (m, 1 H), 3.05 (br, 1H), 3.29 (m, 2 H), 3.35 (m, 2 H), 3.76 (m, 2 H), 3.88 (m, 2 H), 5.10(br, 1 H), 6.47 (d, 1 H), 6.83 (d, 2 H), 6.99 (s, 4 H), 7.01 (m, 3 H),12.16 (s, 1 H);

Analysis for C₂₉H₃₉N₃O₃S Calc'd: C, 60.,71; H, 6.85; N, 7. Found: C,60.44; H, 6.83; N,7.32.

Step e) 5-[4-(2-{[(2S)-3-(4-Butoxyphenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2S)-3-(4-butoxyphenoxy)-2-hydroxypropyl{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, and was obtained as a light yellow solid (72%yield): mp 65° C.; MS m/e 447 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.93 (t,3 H), 1.41 (m, 2 H), 1.64 (m, 2 H), 2.85 (m, 3 H), 3.01 (br, 1 H), 3.89(m, 1 H), 4.09 (br, 1 H), 5.84 (br, 1 H), 6.50 (d,1 H), 6.65 (d, 2 H),6.85 (s, 4 H), 7.06 (m, 3 H), 8.56 (br, 2 H), 12.21 (br,1 H);

Analysis for C₂₆H₃₁N₃O₅S×1 CF₃COOH Calc'd: C, 43.14,; H, 5.49; N, 7.15Found: C, 52.60; H 5.70; N, 6.63.

EXAMPLE 17

5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)(methyl)anilino]-1,3-thiazolidine-2,4-dione.

Step a) (2 S)-1-[(4-Nitrophenethyl)amino]-3-phenoxy-2-propanol

This compound was prepared from (S)-2-(phenoxymethyl)oxirane ( Example6, step a ) and 4-nitrophenylethylamine as described in example 1, stepb, with one modification, the mixture was stirred at 70° C., and wasobtained as an off white solid (73% yield): MS m/e 316 M⁺; ¹H NMR (CDCI₃300 MHz), 1.85 (br, 1 H), 3.0 (m, 6 H), 3.98 (d, 2 H), 4.03 (m, 1 H),6.85 (d, 2 H), 6.99 (t, 1 H), 7.25 (m, 3 H), 7.40 (d, 2 H), 8.18 (d, 2H).

Step b) (1 S)-2-[(tert-Butoxycarbonyl)(4-nitrophenethyl)amino]-1-(phenoxymethyl) ethyl tert-butyl carbonate

This compound was prepared from (2S)-1-[(4-nitrophenethyl)amino]-3-phenoxy-2-propanol and di-tert-butyldicarbonate as described in example 1, step c, with one modification,the reaction was conducted in acetonitrile in the presence of4-(dimethylamino)pyridine, and the product was obtained as a colorlessoil (68% yield): MS m/e 516 (M+H)⁺; ¹H NMR (CDC1₃ 300 MHz) δ1.44 (s, 9H), 1.50 (s, 9 H), 3.0 (br, 2 H), 3.30 (br, 1 H), 3.59 (br, 3 H), 4.01(m, 2 H), (m, 2 H), 5.08 (m, 1 H), 6.85 (d, 2 H), 6.97 (t, 1 H), 7.25(m, 4 H), 8.18 (d, 2 H);

Analysis for C₂₇H₃₆N₂O₈ Calc'd: C, 62.78; H, 7.02; N, 5.42 Found: C,61.91; H, 7.03; N, 5.32.

Step c) (1S)-2-[(4-Aminophenethyl)(tert-butoxycarbonyl)amino]-1-(phenoxymethyl)ethyl tert-butyl carbonate

A mixture of compound from 1S)-2-[(tert-butoxycarbonyl)(4-nitrophenethyl)amino]-1-(phenoxymethyl)ethyltert-butyl carbonate (3.3 g, 6.38 mmol), 10% Pd/C (0.1 g), and ethanol(35 mL) was hydrogenated on a Parr Shaker at 40 psi for 4 hours. Thecatalyst was removed by filtration through celite. Evaporation of thefiltrate gave a colorless oil (93% yield): MS m/s 486 (M+H)⁺; ¹H NMR(CDCI₃ 300 MHz) δ1.24 (d, 18 H), 2.72 (m, 2 H), 3.38 (br, 3 H), 3.59(br, 3 H), 4.02 (br, 2 H), 5.04 (br, 1 H), 6.61 (d, 2 H), 6.88 (d, 2 H),6.97 (m 3 H), 7.26 (d, 2 H).

Step d) (1S)-2-((tert-Butoxycarbonyl){4-[(2,2,2-trifluoroacetyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyltert-butyl carbonate

A mixture of compound from(1S)-2-[(4-aminophenethyl)(tert-butoxycarbonyl)amino]-1-(phenoxymethyl)ethyl tert-butyl carbonate (2.90 g, 5.95 mmol),S-ethyl-trifluorothioacetate (2.38 ml, 18.44 mmol) and methanol (21 mL)was stirred at ambient temperature for 18 hours. Evaporation andpurification by flash chromatography (hexanes/ethyl acetate/methanol7/2.5/0.5) to give a white solid (62% yield): MS m/e 581 (M−H)⁺; ¹H NMR(DMSO-d₆ 300 MHz) δ1.47 (s, 18 H), 2.86 (m, 2 H), 3.32 (br, 1 H), 3.45(br, 2 H), 3.46 (br, 1 H), 4.02 (br, 2 H), 5.11 (br, 1 H), 6.88 (d, 2H), 6.97 (t, 1 H), 7.22 (m, 4 H), 7.48 (d, 2 H), 7.80 (s, 1 H)

Analysis for C₂₉H₃₇F₃N₂O₇ Calc'd: C, 59.78; H, 6.40; N, 4.81 Found: C,59.49; H, 6.42; N, 4.61.

Step e) (1S)-2-((tert-Butoxycarbonyl){4-[methyl(2,2,2-trifluoroacetyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyltert-butyl carbonate

This compound was prepared from (1S)-2-((tert-butoxycarbonyl){4-[(2,2,2-trifluoroacetyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyltert-butyl carbonate and methyl iodide as described in example 1, srepa, and was obtained as a colorless oil. MS m/e 596 M)⁺; ¹H NMR (t300MHz) δ1.48 (s, 18 H), 2.93 (br, 2 H), 3.30 (m, 1 H), 3.34 s, 3 H), 3.50(m, 3 H), 4.10 (br, 2 H), 4.05 (m, 1 H), 5.15 (br, 1 H), 6.90 (d, 2 H),7.15 (t, 1 H), 7.25 (d, 2 H), 7.28 (m, 4 H).

Step f) (1S)-2-{(tert-Butoxycarbonyl)[4-(methylamino)phenethyl]amino}-1-(phenoxymethyl)ethyltert-butyl carbonate

A mixture of (1S)-2-((tert-butoxycarbonyl){4-[methyl(2,2,2-trifluoroacetyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyltert-butyl carbonate (2.1 g, 3.52 mmol), 40% aqueous solution ofpotassium hydroxide (15 mL) and dioxane (10 mL) was stirred at ambienttemperature for 18 hours. The product was extracted withdichloromethane, and dried over K₂CO₃. Evaporation and purification byflash chromatography (hexanes/dichloromethane/methanol (9/0.7/0.3) gavea light yellow oil (1.62 g, 92% yield): MS m/e 500 M⁺; ¹H NMR (CDCI₃ 300MHz), δ1.48 (s, 18 H), 2.93 (br, 2 H), 3.30 (m,1 H), 3.34 s, 3 H), 3.50(m, 3 H), 4.05 (m, 1 H), 4.10 (br, 2 H),5.15 (br, 1 H), 6.56 (d, 2 H),6.86 (d, 2 H), 6.99 (m, 4 H), 7.02 (m, 4 H).

Step g) (1S)-2-((tert-Butoxycarbonyl){4-[(2,4-dioxo-1,3-thiazolidin-5-yl)(methyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyl tert-butyl carbonate

This compound was prepared from (1S)-2-{(tert-butoxycarbonyl)[4-(methylamino)phenethyl]amino}-1-(phenoxymethyl)ethyltert-butyl carbonate and 5-bromo-1,3-thiazolidine-2,4-dione insubstantially the same manner as described in example 1, step d, and wasobtained as an off white solid (50% yield): MS m/e 616 (M+)⁺; ¹H NMR(DMSO-d₆ 300 MHz) δ1.38 (s, 18 H), 2.67 (t, 2 H), 2.74 (s, 3 H), 3.29(m, 2 H), 3.42 (m, 2 H), 4.01 (m, 1 H), 4.02 (m, 1 H), 5.02 (br, 1 H),6.90 (m, 6 H), 7.07 (d, 2 H), 7.28 (t, 2 H), 12.61 (s, 1 H);

Analysis for C₃₁H₄₁N₃O₈ S Calc'd: C, 60.47; H, 6.71; N, 6.82 Found: C,59.23; H, 6.60; N, 6.38.

Step h) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)(methyl)anilino]-1,3-thiazolidine-2,4-dione.

This compound was prepared from (1S)-2-{(tert-butoxycarbonyl)(4-[(2,4-dioxo-1,3-thiazolidin-5-yl)(methyl)amino]phenethyl}amino)-1-(phenoxymethyl)ethyltert-butyl carbonate and trifluoroacetic acid in substantially the samemanner as described in example 1, step e, and was obtained as a whitesolid (31% yield): mp 58° C.; MS m/e 416 (M+H)⁺; ¹H NMR (DMSO-d₆ 300MHz) δ2.76 (m, 3 H), 2.88 (m, 2 H), 3.03 (m, 1 H), 3.22 (m, 2 H), 3.90(m, 2 H), 4.41 (br, 1 H), 5.88 (br, 1 H), 6.94 (m, 6 H), 7.16 (d, 2 H),7.29 (d, 2 H), 8.64 (s, 2 H), 12.36 (s, 1 H);

Analysis for C₁₇H₁₈F₃N₂O₃S×1.3 CF₃COOH×1 H₂O Calc'd: C, 48.68; H, 4.52;N, 7.22 Found: C, 48.93; H 4.59; N, 7.33.

EXAMPLE 18

5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}propyl)anilino]-1,3-thiazolidine-2,4-dione

Step a) (1R)-2-{[2-(4-Aminophenyl)-1-methylethyl]amino}-1-(3-chlorophenyl)-1-ethanol

This compound was prepared from (2 R)-2-(3-chlorophenyl)oxirane and2-(4-aminophenyl)-1-methylethylamine as described in example 1, step b,with one modification, the mixture was stirred in tetrahydrofuran at 70°C. for 48 hours. The product was triturated ethyl ether to give a whitesolid (48% yield): MS m/e 305 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ0.86 (m,3 H),2.23 (m,1 H), 2.53 (m, 2 H), 2.66 (m, 2 H),4.58 (m, 1 H), 5.30 (d,2 H), 5.40 (br,1 H), 6.45 (m, 2 H), 6.77 (m, 2 H), 7.26(m, 4 H).

Step b) tert-butyl 2-(4-Aminophenyl)-1-methylethyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate

This compound was prepared from 1R)-2-{[2-(4-aminophenyl)-1-methylethyl]amino}-1-(3-chlorophenyl)-1-ethanoland di-tert-butyl dicarbonate in substantially the same manner asdescribed in example 1, step c, and was obtained as a colorless oil (68%yield ): MS m/e 405 M⁺.

Step c ) tert-Butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl(2-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenyl}-1-methylethyl)carbamate

This compound was prepared from tert-butyl2-(4-aminophenyl)-1-methylethyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (82%yield): MS m/e 520/522 (M+H)⁺;

Analysis for C₂₅H₃₀CIN₃O₅ S Calc'd: C, 57.74; H, 5.81; N, 8.08 Found: C,57.06; H, 5.88; N, 7.99.

Step d) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}propyl)anilino]-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl(2-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenyl}-1-methylethyl)carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, and was obtained as a white solid (21% yield): mp83-85°;, MS m/e 420/422 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.12 (t, 3 H),3.07 (m, 3 H), 4.01 (br, 1 H), (m, 2 H), 4.93 (t, H), 6.49 (d, 1 H),6.63 (m, 2 H), 7.06 (m, 3 H), 7.43 (m, 3 H), 7.44 (s, 1 H), 8.73 (br, 2H), 12.22 (s, 1 H);

Analysis for C₂₀H₂₂CIN₃O₃S×1.8 CF₃COOH×0.46 H₂O Calc'd: C, 44.70; H,3.90; N, 6.62 Found: C, 44.60; H, 3.79; N, 6.58.

EXAMPLE 19

5-{4-[2-({(2 R)-2-Hydroxy-3-[(2-oxo-2,3-di hydro-1H-benzimidazol-4-yl)oxy]propyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

Step a) 2-Nitro-6-[(2 R)-oxiranylmethoxy]aniline

A mixture of 2-amino-3-nitrophenol (25.3 g, 164.1 mmol), (2S)-(+)oxiranylmethyl 3-nitrobenzenesulfonate (42.5, 164.1 mmol),potassium carbonate (29 g, 209.8 mmol) and acetone (300 mL) was refluxedfor 6 hours. After cooling to room temperature, the mixture wasfiltered, and the filtrate was removed in vacuo. The residue waspartitioned between dichloromethane and water. The organic layer waswashed with aqueous bicarbonate, and dried over MgSO₄. Evaporation andpurification by recrystallization from dichloromethane/hexanes gave anorange colored solid (31 g, 90% yield): MS m/e 210 (M)⁺; Analysis forC₉H₁₀N₂O₄ Calc'd: C, 51.43; H, 4.80; N, 13.33 Found: C, 50.92; H 4.57;N, 13.41.

Step b) (2R)-1-(2-Amino-3-nitrophenoxy)-3-[(4-aminophenethyl)amino]-2-propanolThis compound was prepared from 2-nitro-6-[(2 R)oxiranylmethoxy]anilineand 4-(2-aminoethyl)aniline as described in example 1, step b, with onemodification, the mixture was stirred in tetrahydrofuran at 70° C. for24 hours, and the product was triturated with dichloromethane to give ayellow solid (63% yield): MS m/e 346 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz)δ1.87 (br 1 H), 2.50 (m, 2 H), 2.67 (m, 4 H), 3.82 (m, 1 H), 3.84 (m, 1H), 4.01 (m, 1 H), 4.81 (s, 2 H), 5.24 (s, 1 H),6.46 (d, 2 H), 6.59 (m,1 H), 6.86 (d, 2 H), 7.02 (d, 1 H), 7.22 (s, 2 H), 7.59 (d, 1 H);

Analysis for C₁₇H₂₂N₄O₄ Calc'd: C, 58.95; H, 6.4; N, 16.17 Found: C,58.30; H, 7.15; N, 15.61.

Step c) tert-Butyl (2R)-3-(2-amino-3-nitrophenoxy)-2-hydroxypropyl(4-aminophenethyl)carbamate

This compound was prepared from (2R)-1-(2-amino-3-nitrophenoxy)-3-[(4-aminophenethyl)amino]-2-propanol anddi-tert-butyl dicarbonate as described in example 1, step c, to give ayellow solid (77% yield): MS m/e 447 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz)δ1.36 (s 9 H), 2.59 (m, 2 H), 3.24 (m, 4 H), 3.79 (m, 1 H), 4.00 (m, 2H), 4.81 (s, 2 H), 5.35 (d, 1 H), 6.46 (d, 2 H), 6.55 (t, 1 H), 6.81 (d,2 H), 7.00 (d, 1 H), 7.21 (s, 2 H), 7.57 (d, 1 H);

Analysis for C₂₂H₃₀N₄O₅ Calc'd: C, 59.18; H, 6.77; N, 12.55 Found: C,59.32; H, 6.65; N, 12.81.

Step d) tert-Butyl 4-aminophenethyl[(2R)-3-(2,3-diaminophenoxy)-2-hydroxypropyl]carbamate

This compound was prepared from tert-butyl (2R)-3-(2-amino-3-nitrophenoxy)-2-hydroxypropyl(4-aminophenethyl)carbamateas described in EP 0764640 to give a yellow solid (70% yield): MS m/e417 (M)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.37 (s 9 H), 2.57 (m, 2 H), 3.06(m, 1 H), 3.30 (m, 3 H), 3.63 ( m, 1 H), 3.68 (m, 1 H), 3.98 (m, 1 H),4.16 (br, 2 H), 4.45 (br, 2 H), 4.82 (br, 2 H), 5.13 (d, 1 H), 6.11 (d,1 H), 6.19 (d, 1 H), 6.32 (t, 1 H), 6.45 (d, 2 H), 6.79 (d, 2 H);

Analysis for C₂₂H₃₂N₄O₄ Calc'd: C, 63.44; H, 7.74; N, 13.45 Found: C,62.17; H, 7.53; N, 13.25.

Step d) tert-Butyl 4-aminophenethyl{(2R)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}carbamate

A mixture of tert-butyl 4-aminophenethyl[(2R)-3-(2,3-diaminophenoxy)-2-hydroxypropyl]carbamate (1.0 g, 2.4mmol),1,1-carbonyldiimidazole (0.52 g, 3.2 mmol) and dioxane (20 mL) wasstirred at ambient temperature for 18 hours. The solvent was removed invacuo and the residue was purified by flash chromatography(hexanes/dichloromethane/ethanol 4/4/2) to give an off white solid(0.28g, 26% yield): MS m/e 443 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.37 (s9 H), 2.59 (m, 2 H), 3.31 (m, 3 H), 3.40 (m, 1 H), 3.85 ( m, 1 H), 3.97(d, 2 H), 4.82 (s, 2 H), 4.94 (d, 1 H), 6.43 (d, 2 H), 6.77 (d, 2 H),6.82 (m, 3 H), 10.55 (s, 1 H), 10.61 (s, 1 H).

Step e) tert-Butyl 4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl{(2R)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}carbamate

This compound was prepared from tert-butyl 4-aminophenethyl{(2R)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (31%yield): MS m/e 558 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.31 (s 9H), 2.64(m, 2 H), 3.41 (m, 5 H), 3.84 ( m, 1 H), 3.96 (m, 2 H), 4.92 (m, 1 H),6.45 (m, 1 H), 6.56 (m, 3 H), 6.81 (m, 2 H), 6.97 (m, 2 H), 10.55 (s,1H), 10.59 (s,1 H), 12.25 (br,1 H).

Step f) 5-{4-[2-({(2 R)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl4-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]phenethyl{(2R)-2-hydroxy-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)oxy]propyl}carbamate and trifluoroacetic acid insubstantially the same manner as described in example 1, step e, and wasobtained as a light yellow solid (38%yield): mp 172° C.; MS m/e 458(M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ2.90 (m, 2 H), 3.22 (m, 4 H), 3.98 (m,1 H), 4.05 (m, 1 H), 4.06 (m, 1 H), 5.74 (d, 1 H), 6.50 (d, 1 H), 6.60(m, 4 H), 6.86 (t, 1 H), 7.10 (m, 3 H), 8.56 (s, 2 H), 10.60 (s, 1 H),10.63 (s, 1 H),12.19 (s, 1 H);

Analysis for C₂₁H₂₃N₅O₅S×1 CF₃COOH Calc'd: C, 48.34; H, 4.23; N, 12.25Found: C, 47.79; H, 4.48; N, 11.20.

EXAMPLE 20

5-{[2-({[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}methyl)-1-benzofuran-5-yl]amino}-1,3-thiazolidine-2,4-dione

Step a) 2-(Bromomethyl)-6-nitro-1-benzofuran

Acetoxime (50 g, 355 mmol) was added portionwise into a mixture ofsodium hydride (60% in mineral oil, 15.52 g, 390.5 mmol) andN,N-dimethylformamide. The mixture was stirred for 1 hour. During thisperiod the mixture was allowed to come to room temperature. The mixturewas cooled to 0° C., and 4-fluoro-nitrobenzene 92702 g, 372.7 mmol) wasadded slowly. The new mixture was stirred at 0° C. for 2 hours and thenwas stirred at room temperature for 16 hours. The reaction mixture wasquenched with brine and the precipitated solid filtered and dried togive an off-white solid (66 g). this product was taken in ethanol (1000mL) and anhydrous hydrochloric acid was passed through the mixture for 2hours. The mixture was then refluxed for 20 hours and the volatiles wereremoved in vacuo. The residue was taken in water and the precipitatedsolid filtered and dried to give an off-white solid (50.6 g). thisproduct was taken in carbon tetrachloride and1,3-dibromo-5,5-dimethylhydantoin (40.4 g, 141.2 mmol) and benzoylperoxide were added into the mixture. The mixture was then refluxedunder UV light for 6 hours. The volatiles were removed in vacuo and theresidue was taken in ethyl acetate and washed with water and brine. Theorganic extracts were dried over MgSO₄. Evaporation and crystallizationform ethyl ether/hexanes gave a white solid (59.6 g): ¹H NMR (DMSO-d₆300 MHz) δ5.0 (s, 2 H), 7.24 (s, 1 H), 7.83 (m, 1 H), 8.24 (m, 1 H),8.63 (m, 1 H).

Step b) (6-Nitro-1-benzofuran-2-yl)methanamine

A mixture of 2-(bromomethyl)-6-nitro-1-benzofuran (44.0 g, 171.9 mmol),potassium phthalimide (47.7 mmol), acetonitrile (1000 mL), and 18-C-6(4.5 g, 17.19 mmol) was stirred at room temperature for 10 hours. Thevolatiles were removed in vacuo, and the residue was taken in ethylacetate and washed with water. The organic extracts were dried overMgSO₄. Evaporation and crystallization form ethyl ether/hexanes gave anoff-white solid (53.2 g). This product was taken in ethanol andhydrazine (7.2 mL, 233 mmol) was added. The mixture was refluxed for 5hours and the volatiles were removed in vacuo. The residue was acidifiedwith hydrochloric acid, and the precipitated solids were filtered offand discarded. The filtrate was basified with sodium hydroxide (10 N)and extracted with ethyl acetate. The organic extracts were dried overMgSO₄. Evaporation and crystallization form ethyl ether/hexanes gave abrownish solid (24.6 g): MS m/e 192 M⁺;

Analysis for C₉H₈N₂O₃ Calc'd: C, 56.25; H, 4.20; N, 14.58 Found: C,56.21; H, 4.13; N, 14.41.

Step c) (1R)-1-(3-chlorophenyl)-2-{[(5-nitro-1-benzofuran-2-yl)methyl]amino}-1-ethanol

This compound was prepared from (R)-(+)-3-chlorostyrene oxide and(6-nitro-1-benzofuran-2-yl)methanamine as described in example 1, stepb, to give a yellow solid (67% yield), MS m/e 347 (M+H)⁺; Analysis forC₁₇H₁₅CIN₂O₄ Calc'd: C, 58.88; H, 4.36; N, 8.08 Found: C, 58.75; H,4.36; N, 8.01

Step d) tert-Butyl (2 R)-2-(3-chlorophenyl)-2-hydroxyethyl[(5-nitro-1-benzofuran-2-yl)methyl]carbamate

This compound was prepared from (1R)-1-(3-chlorophenyl)-2-{[(5-nitro-1-benzofuran-2-yl)methyl]amino}-1-ethanoland di-tert-butyl dicarbonate as described in example 1, step c, to givea tan solid (91% yield), MS mle 447 (M+H)⁺.

Step e) tert-Butyl (5-amino-1-benzofuran-2-yl)methyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate

A solution of tert-butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl[(5-nitro-1-benzofuran-2-yl)methyl]carbamate (2.95 g, 6.60 mmol) in methyl alcohol(30 mL) was added over 10 minutes into a slurry of iron (1.76 g, 33mmol) and 0.025 M aqueous ammonium chloride (33 mL). The reactionmixture was warmed up at reflux for 4 hours. The mixture was thenfiltered through celite and washed with hot methyl alcohol. Thevolatiles were removed in vacuo and the residue was neutralized withsaturated aqueous bicarbonate, and extracted with dichloromethane. Theorganic extracts were dried over MgSO₄. Evaporation and purification byrecrystallization from dichloromethane and hexanes gave a tan solid(1.80 g, 65% yield): MS m/e 417 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.34(s 9 H), 3.27 (m, 1 H), 3.45 (m, 1 H), 4.57 (m, 2 H), 4.82 (m, 3 H),5.69 (m, 1 H), 6.52 (m, 2 H), 6.66 (s, 1 H), 7.18 (t, 1 H), 7.31 (m, 4H).

Step f) tert-Butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl({5-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]-1-benzofuran-2-yl}methyl)carbamate

This compound was prepared from tert-butyl(5-amino-1-benzofuran-2-yl)methyl[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate and5-bromo-1,3-thiazolidine-2,4-dione in substantially the same manner asdescribed in example 1, step d, and was obtained as a yellow solid (75%yield), MS m/e 530 (M−H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ1.28 (s 9 H), 3.24(m, 1 H), 3.40 (m, 1 H), 4.54 (m, 2 H), 4.81 (br,1 H), 5.66 (br, 1 H),6.47 (m, 1 H), 6.61 (d, 1 H), 6.65 (d, 1 H), 6.78 (s, 1 H), 6.96 (d, 1H), 7.28 (m, 5 H), 12.16 (s, 1 H).

Step g) 5-{[2-({[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}methyl)-1-benzofuran-5-yl]amino}-1,3-thiazolidine-2,4-dione

This compound was prepared from tert-butyl (2R)-2-(3-chlorophenyl)-2-hydroxyethyl({5-[(2,4-dioxo-1,3-thiazolidin-5-yl)amino]-1-benzofuran-2-yl}methyl)carbamateand trifluoroacetic acid in substantially the same manner as describedin example 1, step e, and was obtained as a light yellow solid(60%yield): mp 70° C.; MS m/e 458 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ3.08(m, 1 H), 3.20 (m, 1 H), 4.42 (m, 2 H), 4.94 (d, 1 H), 6.28 (d, 1 H),6.50 (d, 1 H), 6.78 (d, 1 H), 6.86 (s, 1 H), 6.97 (s, 1 H), 7.05 (d, 1H), 7.34 (m, 5 H), 9.38 (br, 2 H), 11.55 (br, 1 H);

Analysis for C₂₀H₁₈CIN₃O₄S×1 CF₃COOH×0.28 H₂O Calc'd: C, 47.90; H, 3.44;N, 7.62 Found: C, 46.84; H, 3.46; N, 7.12.

EXAMPLE 21

5-(4-{2-[(2S)-2-Hydroxy-3-(naphthalen-2-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

Step a) 2-[(2-Naphthyloxy)methyl]oxirane

NaH (60% in mineral oil, 2.16 g, 54.0 mmol) was added portionwise to 50mL of DMF with stirring at room temperature under a nitrogen atmosphere.A solution of 2-naphthol (6.74 g, 46.28 mmol) in DMF (50 mL) was thenadded dropwise to this suspension over a period of 0.5 hour. Afterstirring for 1 hour a solution of (2 S)-oxiranylmethyl3-nitrobenzenesulfonate (10 g, 38.57 mmol) in DMF (50 mL) was addeddropwise into this mixture over a period of 15 min. The mixture was thenstirred at room temperature overnight. The reaction was quenched withaqueous ammonium chloride to pH 5 and further diluted with water. Theformed solid was isolated by filtration to give (6.14 g, 80% yield): mp:72-73° C.; MS m/z 200 M⁺; Analysis for C₁₃H₁₂O₂ Calc'd: C, 77.98; H,6.04; N, 0.00; Found: C, 78.12; H, 6.63; N, 0.12.

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-(2-naphthyloxy)-2-propanol

A mixture of 2-[(2-naphthyloxy)methyl]oxirane (3.0 g, 15.0 mmol), and2-(4-aminophenyl)ethylamine (6.1 mL, 45.0 mmol) in THF (20 mL) wasstirred at room temperature under a nitrogen atmosphere overnight. Thesolvent was removed in vacuo and the residue was stirred in ethyl ether(4×150 mL) overnight. The solid was isolated by filtration to give anoff-white solid (2.9 g, 58% yield): mp: 112-113° C.; MS m/z 336 M⁺;Analysis for C₂₁H₂₄N₂O₂ Calc'd: C, 74.97; H, 7.19; N, 8.33; Found: C,75.16; H, 7.18; N, 8.48.

Step c) 5-(4-{2-[(2S)-2-Hydroxy-3-(naphthalen-2-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

A mixture of (2S)-1-[(4-aminophenethyl)amino]-3-(2-naphthyloxy)-2-propanol (2.86 g, 8.5mmol), N,N-diisopropylethylamine (3.7 mL, 21.2 mmol) and di-tert-butyldicarbonate (2.25 g, 10.2 mmol) in THF (55 mL) was stirred at roomtemperature under a nitrogen atmosphere for 3 hours. The reaction wasquenched with saturated aqueous sodium bicarbonate and further dilutedwith water. The aqueous layer was extracted with ethyl acetate. Theextract was washed with water, and dried with MgSO₄. Concentration andpurification by flash column chromatography (hexanes/ethyl acetate 1/1)gave a white solid (2.34 g, 63% yield). A mixture of this product (2.3g, 5.27 mmol), triethylamine (0.96 mL, 6.85 mmol) and5-bromodiazolidine-2,4-dione (1.34 g, 6.85 mmol) in DMF (20 mL) wasstirred at room temperature under a nitrogen atmosphere for 7 hours. Themixture was diluted with water and extracted with methylene chloride.The extract was washed with water, and dried with MgSO₄. Evaporation andpurification by flash column chromatography (methylene chloride/methanol95/5) gave a solid (2.15 g, 70% yield). A solution of this product (2.1g, 3.8 mmol), trifluoroacetic acid (14 mL) and methylene chloride (20mL) was stirred at room temperature under a nitrogen atmosphere for 30min. The reaction mixture was concentrated to give an off-white solid(1.88 g, 77% yield): mp: 90-91° C.; MS m/z 452 (M+H)⁺; Analysis forC₂₄H₂₅N₃O₄S×1.3 H₂O×1.0 CF3CO₂H Calc'd: C, 53.02; H, 4.89; N, 7.13;Found: C, 53.28; H, 4.41; N, 6.88.

EXAMPLE 22

5-(4-{2-[(2 S)-3-(Biphenyl-4-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

Step a) 2-[([1,1′-Biphenyl]-4-yloxy)methyl]oxirane

The title compound was prepared from 4-phenylphenol and (2S)-oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 21, step a. The product was obtained as awhite solid: mp: 91-92° C.; MS m/z 226 M⁺; Analysis for C₁₅H₁₄O₂ Calc'd:C, 79.62; H, 6.24; N, 0.00; Found: C, 79.35; H, 6.36; N, −0.03.

Step b) (2 S)-1 -[(4-Aminophenethyl)amino]-3-([1,1′-biphenyl]-4-yloxy)-2-propanol

The title compound was prepared from2-[([1,1′-biphenyl]-4-yloxy)methyl]oxirane, and2-(4-aminophenyl)ethylamine in substantially the same manner, asdescribed in example 21, step b. The product was obtained as a whitesolid: 118-119° C.; MS m/z 362 M⁺; Analysis for C₂₃H₂₆N₂O₂ Calc'd: C,76.21; H, 7.23; N, 7.73; Found: C, 75.83; H, 7.24; N, 7.58.

Step c) 5-(4-{2-[(2S)-3-(Biphenyl-4-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

The title compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-([1,1′-biphenyl]-4-yloxy)-2-propanol,and 5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 21, step c. The product was obtained as a whitesolid: mp: 70-71° C.; MS m/z 478 (M+H)⁺; Analysis for C₂₆H₂₇N₃O₄S×0.36DMF×2.0 F₃CCO₂H Calc'd: C, 49.54; H, 4.54; N, 6.25; Found: C, 49.56; H,4.27; N, 6.22.

EXAMPLE 23

5-(4-{2-[2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

Step a) 2-[(1-Naphthyloxy)methyl]oxirane

The title compound was prepared from 1-naphthol and (2 S)-oxiranylmethyl3-nitrobenzenesulfonate in substantially the same manner as described inexample 21, step a. The product was obtained as an oil: MS mlz 200 M⁺.

Step b) (2 S)-1-[(4-Aminophenethyl)amino]-3-(1-naphthyloxy)-2-propanol

The title compound was prepared from 2-[(1-naphthyloxy)methyl]oxirane,and 2-(4-aminophenyl)ethylamine in substantially the same manner, asdescribed in example 21, step b. The product was obtained as a lightyellow sticky solid: 107-108° C.; MS m/z 337 (M+H)⁺; Analysis forC₂₁H₂₄N₂O₂ Calc'd: C, 74.97; H, 7.19; N, 8.33; Found: C, 74.56; H, 7.36;N, 8.49.

Step c) 5-(4-{2-[2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

The title compound was prepared from (2S)-1-[(4-aminophenethyl)amino]-3-(1-naphthyloxy)-2-propanol, and5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 21, step c. The product was obtained as anoff-white solid: mp: 61-62° C.; MS m/z 452 (M+H)⁺; Analysis forC₂₃H₂₇N₄O₄S Na×1.6 H₂O×1.5 CF₃CO₂H Calc'd: C, 49.79; H, 4.60; N, 6.45;Found: C, 50.16; H, 4.22; N, 6.08.

EXAMPLE 24

5-(4-{2-[(2 S)-3-(Benzo[1,3]dioxol-5-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

Step a) 5-(2-Oxiranylmethoxy)-1,3-benzodioxole

The title compound was prepared from 3,4-methylenedioxyphenol and (2S)-oxiranylmethyl 3-nitrobenzenesulfonate in substantially the samemanner as described in example 21, step a. The product was obtained asan oil: MS m/z 124 M⁺; Analysis for C₁₅H₁₄O₂ Calc'd: C, 61.85; H, 5.19;N, 0.00; Found: C, 61.53; H, 5.22; N, 0.14.

Step b) (2S)-1-[(4-Aminophenethyl)amino]-3-(1,3-benzodioxol-5-yloxy)-2-propanol

The title compound was prepared from5-(2-oxiranylmethoxy)-1,3-benzodioxole and 2-(4-aminophenyl)ethylaminein substantially the same manner, as described in example 21, step b.The product was obtained as a solid: 96-97° C.; MS m/z 331 (M+H)⁺;Analysis for C₁₈H₂₂N₂O₄ Calc'd: C, 65.44; H, 6.71; N, 8.48; Found: C,65.26; H, 6.63; N, 8.52.

Step c) 5-(4-{2-[(2S)-3-(Benzo[1,3]dioxol-5-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione

The title compound was prepared from (2 S)-1-[(4-aminophenethyl)amino]-3-(1,3-benzodioxol-5-yloxy)-2-propanol, and5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 21, step c. The product was obtained as anoff-white solid: mp: 65° C. (decomposed); MS m/z 446 (M+H)⁺; Analysisfor C₂₁H₂₃N₃O₆S×0.87 H₂O×1.0 CF₃CO₂H Calc'd: C, 48.31; H, 4.66; N, 7.19;Found: C, 48.51; H, 4.49; N, 7.08.

EXAMPLE 25

5-[(4-{2-[(2 S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-(4-bromo-benzyl)-amino]-thiazolidine-2,4-dione

Step a) tert-Butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(4-bromobenzyl)amino]phenethyl}carbamate

A mixture of tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate (0.20 g, 0.41mmol), 4-bromobenzyl bromide (0.16 g, 0.62 mmol) and potassium carbonate( 0.08 g, 0.62 mmol) in acetone (2.2 mL) was stirred at room temperaturefor two days. The mixture was diluted with water and extracted withethyl acetate. The extract was washed with water and dried with MgSO₄.Evaporation and purification by flash column chromatography(hexane/ethyl acetate 7/3) gave a white solid (0.06 g, 21%): MS m/z 661[M+H]⁺.

Step b) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-(4-bromo-benzyl)-amino]-thiazolidine-2,4-dione

The title compound was prepared from tert-butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl{4-[(4-bromobenzyl)amino]phenethyl}carbamate,and 5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 4. The product was obtained as a light yellowsolid: mp: 50-52° C.; MS m/z 676 [M+H]⁺; Analysis for C34H₃₄BrN₃O₅S×1.6CF₃CO₂H Calc'd: C, 52.01; H, 4.18; N, 4.89; Found: C, 51.73; H, 4.27; N,4.57.

EXAMPLE 26

5-[(4-{2-[(2 S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-methyl-amino]-thiazolidine-2,4-dione

Step a) tert-Butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl[4-(methylamino)phenethyl]carbamate

The title compound was prepared from tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate and iodomethane insubstantially the same manner, as described in example 25, step a. Theproduct was obtained as an oil. MS m/z 507 [M+H]⁺.

Step b) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-methyl-amino]-thiazolidine-2,4-dione

The title compound was prepared from tert-butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl[4-(methylamino)phenethyl]carbamate,and 5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 4. The product was obtained as an off-white solid;mp: 51-53° C.; MS m/z 522 (M+H)⁺; Analysis for C₂₈H₃₁N₃O₅S×1.0 CF₃CO₂HCalc'd: C, 56.69; H, 5.07; N, 6.61; Found: C, 57.66; H, 4.57; N, 6.10.

EXAMPLE 27

5-[(4-{2-[(2 S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-[3-(4-fluoro-phenyl)-prop-2-ynyl]-amino}-thiazolidine-2,4-dione

Step a) tert-Butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl(4-{[3-(4-fluorophenyl)-2-propynyl]amino}phenethyl)carbamate

The title compound was prepared from tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate, and1-(3-bromo-1-propynyl)-4-fluorobenzene (U.S. Pat. No. 5,574,051) insubstantially the same manner, as described in example 25, step a. Theproduct was obtained as a semi-solid: MS m/z 625 [M+H]⁺.

Step b) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-[3-(4-fluoro-phenyl)-prop-2-ynyl]-amino}-thiazolidine-2,4-dione

The title compound was prepared from tert-butyl (2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl(4-{[3-(4-fluorophenyl)-2-propynyl]amino}phenethyl)carbamate,and 5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 4. The product was obtained as an off-white solid:mp: 99-101° C.; MS m/z 640 (M+H)⁺; Analysis for C₃₆H₃₄FN₃O₅S×0.27H₂O×0.24 CF₃CO₂H Calc'd: C, 65.21; H, 5.22; N, 6.25; Found: C, 65.52; H,5.25; N, 6.16.

EXAMPLE 28

5-[(4-Bromo-benzyl)-(4-{2-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-phenyl)-amino]-thiazolidine-2,4-dione

Step a) tert-Butyl 4-aminophenethyl[(2 S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate

A mixture of tert-butyl 4-aminophenethyl{(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl}carbamate (0.54 g, 1.1mmol), and 10% Pd-C (0.05 g) in ethanol (30 mL) was hydrogenated at roomtemperature at 50 psi for 5.5 hours. Filtration and evaporation yieldedan oil. MS m/z 401 (M−H)⁻.

Step b) tert-Butyl 4-[(4-bromobenzyl)amino]phenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate

The title compound was prepared from tert-butyl 4-aminophenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate and iodomethane insubstantially the same manner, as described in example 4. The productwas obtained as a white solid: MS m/z 571 [M+H]⁺.

Step c) 5-[(4-Bromo-benzyl)-(4-{2-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-phenyl)-amino]-thiazolidine-2,4-dione

The title compound was prepared from tert-butyl4-[(4-bromobenzyl)amino]phenethyl[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]carbamate, and5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 4. The product was obtained as an off-white solid:mp: 79° C. (decomposed); MS m/z 584 (M−H)⁻; Analysis forC₂₇H₂₈BrN₃O₅S×0.59 H₂O×1.0 CF₃CO₂H Calc'd: C, 48.98; H, 4.28; N, 5.91;Found: C, 48.77; H, 4.32; N, 5.54.

EXAMPLE 29

5-((4-Bromo-benzyl)-{4-[2-((2 S)-2-hydroxy-3-phenoxy-propylamino)-ethyl]-phenyl}-amino)-thiazolidine-2,4-dione

Step a) tert-Butyl 4-[(4-bromobenzyl)amino]phenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate

A mixture of (2 S)-1-[(4-aminophenethyl)amino]-3-phenoxy-2-propanol(0.503 g, 1.76 mmol), N,N-diisopropylethylamine (0.765 mL, 4.4 mmol) anddi-tert-butyl dicarbonate (0.461 g, 2.11 mmol) in THF (11 mL) wasstirred at room temperature under a nitrogen atmosphere for 3 hours. Thereaction was quenched with saturated aqueous sodium bicarbonate andfurther diluted with water. The aqueous layer was extracted with ethylacetate. The extract was washed with water, dried with MgSO₄ andconcentrated to give a light brown solid (0.45 g, 66%). A mixture ofthis product (0.44 g, 1.14 mmol), 4-bromobenzyl bromide (0.58 g, 2.28mmol) and potassium carbonate (0.31 g, 2.28 mmol) in acetone (6 mL) wasstirred at room temperature for 6 hours. The mixture was diluted withwater and extracted with ethyl acetate. The extract was washed withwater and dried with MgSO₄. Evaporation and purification by flash columnchromatography (hexane/ethyl acetate 7/3) gave an oil (0.33 g, 53%): mp:° C; MS m/z 555 [M+H]⁺.

Step b) 5-((4-Bromo-benzyl)-{4-[2-((2S)-2-hydroxy-3-phenoxy-propylamino)-ethyl]-phenyl}-amino)-thiazolidine-2,4-dione

The title compound was prepared from tert-butyl4-[(4-bromobenzyl)amino]phenethyl[(2S)-2-hydroxy-3-phenoxypropyl]carbamate, and 5-bromodiazolidine-2,4-dionein substantially the same manner, as described in example 4. The productwas obtained as an off-white solid: mp: 52-54° C.; MS m/z 570 (M+H)⁺;Analysis for C₂₇H₂₈BrN₃O₄S×0.6 H₂O×1.5 CF₃CO₂H Calc'd: C, 47.89; H,4.11; N, 5.59; Found: C, 47.54; H, 4.08; N, 5.22.

EXAMPLE 30

5-{4-[2-((2 S)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylamino}-thiazolidine-2,4-dione

Step a) 3-[(2 S)-Oxiranyl]pyridine

A solution of borane-THF (1 M solution, 15 mL) was added dropwise to a0° C., stirred solution of (S)-2-methyl-CBS-oxazaborolidine monohydrate(0.738 g, 2.5 mmol) in THF (10 mL) over a period of 10 min. Afterstirred at 0° C. for 10 minutes the mixture was then added dropwise intoa cold (0° C.) stirred suspension of 3-(2-bromoacetyl)pyridinehydrobromide (7.0 g, 24.9 mmol) in THF (50 mL) over a period of 10minutes. After addition was completed the mixture was stirred at roomtemperature under a nitrogen atmosphere overnight. The reaction wascooled to 0° C. and quenched with dry HCI (0.5 M in methanol, 9 mL) Themixture was further diluted with water and extracted with ethyl acetate.The extract was washed with water and dried with MgSO₄. Evaporation andpurification by flash column chromatography (methylene chloride/methanol95/5) gave (1 R)-2-bromo-1-(3-pyridinyl)-1-ethanol as a brown oil (1.72g, 34%). This solid (1.71 g, 8.5 mmol) was dissolved in THF (15 mL) and5 N aqueous sodium hydroxide (30 mL) was added. After the solution wasstirred at room temperature for 10 minutes, the mixture was diluted withwater and extracted with methylene chloride. The extract was washed withwater, dried with MgSO₄, and concentrated to give a white solid (0.72 g,72%): MS m/z 122 (M+H)⁺.

Step b) (1 S)-2-[(4-Aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol

The title compound was prepared from 3-[(2 S)-oxiranyl]pyridine, and2-(4-aminophenyl)ethylamine in substantially the same manner, asdescribed in example 21, step b. The product was obtained as anoff-white solid: 82-83° C.; MS m/z 258 (M+H)⁺.

Step C) 5-{4-[2-((2S)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylamino}-thiazolidine-2,4-dione

The title compound was prepared from (1S)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol, and5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 21, step c. The product was obtained as a yellowsolid: mp: 46-48° C.; MS m/z 373 (M+H)⁺; Analysis for C₁₈H₂₀N₄O₃S×1.5H₂O×2.5 CF₃CO₂H×0.1 C₂H₅O Calc'd: C, 40.62; H, 3.86; N, 8.09; Found: C,40.87; H, 3.67; N, 7.78.

EXAMPLE 31

5-{4-[2-((2 R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylamino}-thiazolidine-2,4-dione

Step a) 3-[(2 R)-Oxiranyl]pyridine

The title compound was prepared from 3-(2-bromoacetyl)pyridinehydrobromide, and (R)-2-methyl-CBS-oxazaborolidine monohydrate insubstantially the same manner, as described in example 30, step a. Theproduct was obtained as an oil. MS m/z 121 M⁺.

Step b) (1 R)-2-[(4-Aminophenethyl)amino]-1-(3-pyridi nyl)-1-ethanol

The title compound was prepared from 3-[(2 R)-oxiranyl]pyridine, and2-(4-aminophenyl)ethylamine in substantially the same manner, asdescribed in example 30, step b. The product was obtained as a lightbrown solid: MS m/z 258 (M+H)⁺.

Step c) 5-{4-[2-((2R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenylaminol}-thiazolidine-2,4-dione

The title compound was prepared from (1R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol, and5-bromodiazolidine-2,4-dione in substantially the same manner, asdescribed in example 30, step c. The product was obtained as a yellowsolid: mp: 65-67° C.; MS m/z 373 (M+H)⁺; Analysis for C₁₈H₂₀N₄O₃S×1.26H₂O×2.2 CF₃CO₂H Calc'd: C, 41.65; H, 3.86; N, 8.67; Found: C, 41.86; H,3.81; N, 8.24.

What is claimed is:
 1. A compound of formula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylaikoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7-14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof. 2.The compound according to claim 1, wherein R₁, R₂, R₃ are each,independently, hydrogen, alkyl of 1-6 carbon atoms, aryl of 6 to 10carbon atoms, aryloxy of 6-10 carbon atoms, halogen, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, or alkylsulfonylamino of 1-6 carbon atoms; or two of R₁,R₂, and R₃ are taken together to form a heterocyclic ring which is fusedto the ring which contains the R₁, R₂, or R₃ substituents, wherein theheterocyclic ring contains 1-3 heteroatoms selected from N, O, or S; R₄is hydrogen or alkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6carbon atoms, halogen substituted arylalkyl of 7-14 carbon atoms, orarylalkyne of 8-16 carbon atoms; R₆ is hydrogen, or alkyl of 1-6 carbonatoms; A is phenyl, or benzofuryl; X is bond, or —OCH₂—; Y is alkyl of1∝6 carbon atoms; Z is sulfur; W is carbon; or a pharmaceuticallyacceptable salt thereof.
 3. The compound of claim 1, which is a)5-[4-(2-{[(2S)-2-Hydroxy-3-(4-phenoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; b) 5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-3-methyl-1,3-thiazolidine-2,4-dione; c) 5-[4- (2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)anilino]- 3- methyl-1,3-thiazolidine-2,4-dione; d) 5-{4-[2-({(2S)-3-[4-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione; e) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)anilino]- 1,3-thiazolidine-2,4-dione; f) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxy-ethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; g) 5-[4-(2-{[(2R)-2-Hydroxy-2-phenylethyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; h) 5-[4-(2-{[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; i) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; j) 5-[4-(2-{[(2S)-2-Hydroxy-3-(4-methoxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; k) 5-{4-[2-({(2S)-3-[3-(Benzyloxy)phenoxy]-2-hydroxypropyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione; l) 5-[4-(2-{[(2S)-2-Hydroxy-3-(3-hydroxyphenoxy)propyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; m) 5-[4-(2-{[(2 S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; n) N-{5-[(1S)-2-({4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)amino]phenethyl}amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide; o) 5-[4-(2-{[(2S)-3-(1-Benzofuran-5-yloxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; p) 5-[4-(2-{[(2S)-3-(4-Butoxyphenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-1,3-thiazolidine-2,4-dione; q) 5-[4-(2-{[(2S)-2-Hydroxy-3-phenoxypropyl]amino}ethyl)(methyl)anilino]-1,3-thiazolidine-2,4-dione.; r) 5-[4-(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}propyl)anilino]-1,3-thiazolidine-2,4-dione; s) 5-{4-[2-({(2R)-2-Hydroxy-3-[(2-oxo-2,3-dihydro-1 H-benzimidazol-4-yl)oxy]propyl}amino)ethyl]anilino}-1,3-thiazolidine-2,4-dione; t)5-{[2-({[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}methyl)-1-benzofuran-5-yl]amino}-1,3-thiazolidine-2,4-dione; u) 5-(4-{2-[(2S)-2-Hydroxy-3-(naphthalen-2-yloxy)-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione; v) 5-(4-{2-[(2S)-3-(Biphenyl-4-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione; w)5-(4-{2-[2-Hydroxy-3-(naphthalen-1-yloxy)-propylamino]-ethyl}-phenylamino)- thiazolidine-2,4-dione; x) 5-(4-{2-[(2S)-3-(Benzo[1,3]dioxol-5-yloxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione; y) 5-(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenylamino)-thiazolidine-2,4-dione; z) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-(4-bromo-benzyl)-amino]-thiazolidine-2,4-dione; aa) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-methyl-amino]-thiazolidine-2,4-dione; bb) 5-[(4-{2-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-phenyl)-[3-(4-fluoro-phenyl)-prop-2-ynyl]-amino}-thiazolidine-2,4-dione;cc) 5-[(4-Bromo-benzyl)-(4-{2-[(2 S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-phenyl)-amino]-thiazolidine-2,4-dione; dd)5-((4-Bromo-benzyl)-{4-[2-((2 S)-2-hydroxy-3-phenoxy-propylamino)-ethyl]- phenyl}-amino)-thiazolidine-2,4-dione; or a pharmaceuticallyacceptable salt thereof.
 4. A method of treating metabolic disordersmediated by insulin resistance or hyperglycemia in a mammal in needthereof which comprises treating said mammal with an effective amount ofa compound of formula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof.
 5. Amethod of treating or inhibiting type II diabetes in a mammal in needthereof which comprises treating said mammal with an effective amount ofa compound of Formula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof.
 6. Amethod of modulating glucose levels in a mammal in need thereof whichcomprises treating said mammal with an effective amount of a compound offormula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof.
 7. Amethod of treating or inhibiting urinary incontinence in a mammal inneed thereof which comprises treating said mammal with an effectiveamount of a compound of formula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof.
 8. Amethod of treating or inhibiting atherosclerosis, gastrointestinaldisorders, neurogenetic inflammation, glaucoma, or ocular hypertensionin a mammal in need thereof, which comprises treating said mammal withan effective amount of a compound of formula I having the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkyisulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof.
 9. Apharmaceutical composition which comprises a compound of formula Ihaving the structure

wherein, R₁, R₂, R₃ are each, independently, hydrogen, alkyl of 1-6carbon atoms, aryl of 6 to 10 carbon atoms, aryloxy of 6-10 carbonatoms, halogen, trifluoromethyl of 1- 6 carbon atoms, arylalkoxy of 7-14carbon atoms, arylalkyl of 7-14 carbon atoms, alkoxy of 1-6 carbonatoms, hydroxy, nitro, amino, aminocarbonyl, alkylamino of 1-6 carbonatoms, dialkyl amino of 1-6 carbon atoms per alkyl group, formamido,ureido, acyl of 2-7 carbon atoms, acylamino of 2-7 carbon atoms, amino,alkylsulfonylamino of 1-6 carbon atoms, or arylsulfonylamino of 6 to 10carbon atoms; or two of R₁, R₂, and R₃ are taken together to form aphenyl ring or a heterocyclic ring which is fused to the ring whichcontains the R₁, R₂, or R₃ substituents, wherein the heterocyclic ringcontains 1-3 heteroatoms selected from N, O, or S; R₄ is hydrogen oralkyl of 1-6 carbon atoms; R₅ is hydrogen, alkyl of 1-6 carbon atoms,aryl of 6-10 carbon atoms, arylalkyl of 7- 14 carbon atoms, halogensubstituted arylalkyl of 7-14 carbon atoms, arylalkene of 8-16 carbonatoms, arylalkyne of 8-16 carbon atoms, alkoxycarbonyl of 2-7 carbonatoms, aryloxycarbonyl of 7-11 carbon atoms, alkylsulfonyl of 1-6 carbonatoms, or arylsulfonyl of 1-6 carbon atoms; R₆ is hydrogen, alkyl of 1-6carbon atoms, aryl or arylalkyl of 7-14 carbon atoms; A is phenyl,naphthyl, benzofuryl, or benzothienyl; X is bond, —OCH₂—, or —SCH₂—; Yis alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms; Z issulfur; W is carbon; or a pharmaceutically acceptable salt thereof, anda pharmaceutical carrier.